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Available online 31 October 2008resents a fascinating process in which two morphologically distinct tissue types
must derive fromone simple epithelium. These two tissue types, exocrine (including acinar cells, centro-acinar
cells, and ducts) and endocrine cells serve disparate functions, and have entirely different morphology. In
addition, the endocrine tissue must become disconnected from the epithelial lining during its development.
The pancreatic development ﬁeld has exploded in recent years, and numerous published reviews have dealt
speciﬁcally with only recent ﬁndings, or speciﬁcally with certain aspects of pancreatic development. Here I
wish to present amore comprehensive reviewof all aspects of pancreatic development, though still there is not
a room for discussion of stem cell differentiation to pancreas, nor for discussion of post-natal regeneration
phenomena, two important ﬁelds closely related to pancreatic development.
© 2008 Published by Elsevier Inc.Basic pancreatic embryology
In order to form the mature architecture of the pancreas (see Fig. 1),
there is a carefully orchestrated series of embryologic events that must
take place. The ﬁrst morphologic evidence of the pancreas is a
condensation of mesenchyme overlying the dorsal aspect of the
endodermal gut tube in the duodenal anlage of the foregut, just distal
to the stomach. Shortly after this condensation, on the 26th day of
gestation in humans, and at approximately 9.5 days gestation in mice
(E9.5, where E0.5 is deﬁned as noon of the day of discovering a vaginal
plug) with signiﬁcant variation among strains (personal observation) at
approximately the 25th somite stage, the endoderm evaginates into the
overlying mesenchyme. (Kallman and Grobstein, 1964; Pictet and
Rutter, 1972; Pictet et al., 1972; Munger, 1958). Over the ensuing few
hours in the mouse, the dorsal bud evagination continues to elongate,
with a wide opening and an apparent lack of cell division (Wessels and
Cohen, 1967). This initial dorsal bud arises just before loss of contact of
the dorsal gut tubewith the notochord due to fusion of the paireddorsal
aortas in themidline that intervenes between the notochord and dorsal
gut (Pictet and Rutter, 1972) (see Fig. 2). Also, the coelomic epithelium,
whichat this timemakes up theonlymesenchymearound thepancreas,
moves dorsally and begins to compartmentalize the pancreas and gut
away from dorsal aorta and from other dorsal non-gut structures. It is
also during this time thatwe see proliferation of themesenchymal cells
in between the coelomic epithelium and pancreatic epithelium (Pictet
and Rutter, 1972). Approximately 12 h after dorsal bud evagination in
the mouse, and 6 days after dorsal bud evagination in humans, the
ventral bud begins to arise from the caudal aspect of the hepatic/biliary
bud evagination, through a process that morphologically is similar
to the dorsal bud, but the molecular control of ventral pancreaslsevier Inc.development is markedly different from that of the dorsal pancreas.
Once evaginated, the pancreatic buds undergo elongation of a stalk
region and branching morphogenesis of the more apical region of the
bud. This branchingmorphogenesis appears to follow a unique pattern.
Unlike the more typical 90° outgrowth pattern of branching morpho-
genesis seen in developing lung, kidney and salivary glands, the
pancreas undergoes acute angle branchingwhich, due to the proximity
to one another of new adjacent branches, tends to exclude intervening
mesenchyme. This exclusion of mesenchyme may in turn inﬂuence
epithelial–mesenchymal interactions and lineage selection (see Fig. 3).
During this early developmental period, little cellular ultrastructural
differentiation is seen, except that some endocrine granules become
visible. Also during this early phase, as a result of both gut rotation and
elongation of the dorsal and, especially, the ventral stalk (these stalks
will give rise to the main pancreatic ducts), ventral and dorsal buds
come into contact with one another within the forming C-loop of the
duodenal anlage. This contact and then fusion of the buds occurs
around E12 to 13 in themouse, and E37 to 42 in humans. Coalescence of
the two buds leads to fusion of the ventral bud duct with the distal
portion of the dorsal bud duct. This fused duct runs the entire length of
the pancreas, and is termed the duct of Wirsung. The proximal portion
of the dorsal bud duct persists as the smaller (accessory) duct of
Santorini. Thus, the future duct of Wirsung originates from both the
ventral bud epithelium and the distal dorsal bud epithelium, whereas
the future duct of Santorini originates only from theproximal portion of
the dorsal bud epithelium.
At approximately E13 to 14 in the mouse, dramatic changes occur
in the cellular architecture of the pancreas. Beyond the early,
predominantly glucagon-positive endocrine cells, there is then a
major ampliﬁcation of endocrine cell numbers, particularly β-cells,
during what has been termed the “secondary transition.” Similarly,
rapid branching morphogenesis and acinar cell differentiation occurs,
Fig. 1. The elegant architecture of the mature pancreas consists of the endocrine islets of
Langerhans, the digestive enzyme-secreting acinar cells contained in clusters of acini,
and the acinar-draining ducts with accompanying blood vessels and lymphatics. Other
than the vessels, the pancreas has very little mesenchyme-derived tissue. Interestingly,
the complex epithelium-derived structures are all formed from a single-cell thick sheet
of foregut endoderm.
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expression, development of large amounts of rough endoplasmic
reticulum, and formation of zymogen granules. It is at this time that
the pancreas becomes opaque to the naked eye due to the large
amount of zymogen granules. Similarly, insulin levels undergo a
300,000-fold increase between E12 and 20 in the rat, compared with
only a 1000-fold increase in the number of insulin-positive cells
present (Clark and Rutter,1972). Early in gestation,measured glucagon
levels are 1000-fold higher than insulin, but relative glucagon levels
diminish rapidly as the pancreas grows (Pictet and Rutter, 1972).
Pancreatic endocrine cells
Glucagon-containing α-granules are ﬁrst seen at E9 in the mouse
(Pictet et al., 1972). Insulin-containing β-granules are not typically
seen until the secondary transition period. Morphologically, the
earliest endocrine cells are integrated in amongst the exocrine/
epithelial cells, and maintain contact with the lumen. Interestingly,
the lumen at these early times can be difﬁcult to appreciate, and only
by careful topographical image analysis does it become clear that what
seems to be a thick, multi-layered epithelium is actually a single sheet
of cells with a highly convoluted, imbricated lumen. These epithelial
cells maintain critical tight junction connections with adjacent
epithelial cells and retain E-cadherin positivity. It is at this time that
a key morphologic transition occurs. Endocrine cells, typicallyFig. 2. (A) The close relationship between the dorsal aspect of the gut endoderm and the no
E8.5–9.0 to intervene between the gut epithelium and notochord. (C) The mesenchyme has
E9.0–9.5 (with permission, Slack, 1995).glucagon-positive, convert to non-epithelial cells and lose connection
with the lumen and tight junctions. This conversion to non-epithelial
location of endocrine cells has been postulated to entail a change in
cell division polarity, from perpendicular to the basement membrane
to parallel to the basement membrane (Pictet and Rutter, 1972). There
appears also to be down regulation of pdx1 (a key marker of early
pancreatic progenitor cells) in these endocrine progenitor cells as they
become non-epithelial. This conversion process has been postulated
to parallel epithelium-to-mesenchyme transformation.
Over the next several days (E14 to E18 in the mouse pancreas) the
demarginating new endocrine cells begin to accumulate along the
ducts andblood vessels in a cord-like linear pattern (see Fig. 4). Over the
next few days, and then continuing after birth, these linear endocrine
collections coalesce into aggregates that represent the ﬁrst islets of
Langerhans, which consist of insulin-producing β-cells, glucagon-
producing α-cells, somatostatin-producing δ-cells, pancreatic poly-
peptide-producing PP cells, and ghrelin-producing ɛ-cells.
Early tissue interactions
The exceedingly complex repertoire of morphologic events that
occur during pancreatic development, together with the similarly
complex pattern of cellular differentiation and lineage selection,
appear to all be mediated in great part by tissue interactions.
Pancreas development has classically been described as an epithe-
lial–mesenchymal process. However, prior to the presence of
pancreatic mesenchyme other key tissue interactions are known to
occur.
During gastrulation in chicken and zebraﬁsh, FGF4 signals from the
mesectoderm to the endoderm to induce the dorsal foregut to become
competent to receive permissive pro-pancreatic notochord signals
(Wells and Melton, 2000). In zebraﬁsh, subsequent instructive
gastrulation signals for the anterior foregut to become competent to
receive pro-pancreatic notochord signals come in the form of retinoic
acid and/or BMPs (Stafford and Prince, 2002; Tiso et al., 2002). Early
after gastrulation, as the foregut endoderm curls up and closes
ventrally, the dorsal aspect of the endoderm in the prepancreatic
region is in contact with the notochord, and the ventral pancreas is in
contact with the lateral plate mesoderm (Kumar et al., 2003).
Notochord
Once the gut tube is established, the development of the dorsal
pancreas is then controlled by the notochord, through permissive
interactions. In mice, the notochord is in contact with the dorsal
prepancreatic endoderm from the time of notochord formation up
until E8 (somite 13), at which time the paired dorsal aortas fuse in the
midline to intervene between the notochord and the dorsal foregut
(see Fig. 5). Kim et al., showed elegantly that notochord removal from
early chicken embryos in vitro (9 somite stage, which is far in advancetochord at E8 is shown. (B) The two paired dorsal aortae have fused in the midline by
proliferated to create a distance between the dorsal epithelium and the dorsal aorta by
Fig. 3. Schematic representation of epithelial–mesenchymal interactions. Early, at E9–9.5, there is a condensation of mesenchyme that subsequently, within the next 12 to 24 h, leads
to an evagination of the epithelium. This evagination is followed shortly by the onset of branching morphogenesis, but unlike most branching organs, the pancreas has a more acute
angle to its branches (rather than the 900 branching seen in lung and kidney), resulting in subsequent exclusion of most of the mesenchyme fromwithin the clefts of the branched
epithelium (see insert). This relative exclusion of mesenchyme may predispose to endocrine differentiation, since the absence of contact with mesenchyme is thought to lead to
endocrine differentiation (putative endocrine progenitor region shown in the green dotted-line box in the insert).
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somites) prevented proper dorsal pancreas formation and inhibited
expression of pancreas-speciﬁc genes (Kim et al., 1997). Neither the
global endoderm marker HNF3β nor ventral pancreas development
was affected. Interestingly, there were still forme fruste dorsal bud/
branching events in the absence of notochord. In a subsequent study
from the same laboratory, Hebrok et al., followed up on an incidental
observation that sonic hedgehog (Shh, which they had used as a
marker of notochord) was speciﬁcally absent in the prepancreatic
endoderm (Hebrok et al., 1998). Grafting experiments with chicken
endoderm showed that notochord proximity to the endoderm could
suppress Shh expression. Similarly, deleting notochord in explanted
chick embryo cultures resulted in Shh expression ectopically in the
pancreatic region, with failure of pancreatic development (see Fig. 5).
Also, implantation of an ectopic additional notochord could cause
suppression of endodermal Shh, with ectopic induction of cell-shape
changes similar to early pancreas formation. The role of hedgehog
signaling in pancreatic development is discussed in detail the
“Hedgehog signaling” section. Using a candidate approach of knownFig. 4. Mid-gestation endocrine cells develop as periductal accumulations. (A) Whole-mou
insulin cells (with permission, Slack, 1995). (B) Histologic sections with insulin in yellow, duct
cells. (C) A TGF-β receptor II mutant mouse with ampliﬁcation of these periductal cord-likenotochord-produced morphogens, activin βB and FGF2 at physiologic
concentrations were found to be able to replace the notochord effect.
Based on the observation that exogenous Shh could override the
pancreas-inducing effect of activin βB, and that the notochord makes
Shh, it seems that Shh itself must be a key anti-pancreatic factor,
rather than merely being a marker of non-pancreatic endoderm.
The ventral pancreas derives fromventral endoderm (which has no
contact with the notochord) under the control of signals from the
overlying cardiogenic mesenchyme. Pro-hepatic signals such as FGF's
induce liver formation from the ventral endoderm at the expense of
ventral pancreas formation. Absence of FGF's and cardiogenic
mesenchyme, however, will lead to “default” differentiation into
ventral pancreas (Deutsch et al., 2001b).
Endothelium
As mentioned above, the notochord loses contact with the dorsal
pre-pancreatic endoderm due to fusion of the paired aortas in the
midline in between notochord and endoderm. The endothelium hasnt insulin-staining of E15 mouse pancreas showing the cord-like arrangement of the
s in green, amylase in blue showing the cord-like distribution of the ducts and endocrine
structures is shown for emphasis (Tulachan et al., 2007).
Fig. 5. The role of sonic hedgehog signaling between the notochord and the foregut. (A) The notochord is shown in proximity to the median part of the endoderm prior to the
endoderm forming the gut tube. (B) As the gut tube forms, Sonic hedgehog is expressed throughout the gut epithelium (e), as noted herewith in situ hybridization. The notochord (n),
which also stains strongly for sonic hedgehog, is distant from the gut epithelium in this non-pancreatic region of the foregut, so sonic hedgehog is expressed in the foregut at this level
(arrowheads). (C) An ectopic notochord (arrowhead) placed adjacent to non-pancreatic foregut epithelium leads to suppression of sonic hedgehog and subsequent ectopic pancreas
formation (with permission, Hebrok et al., 1998).
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al. showed an inductive role for the early aortic endothelium (Lammert
et al., 2001) (see Fig. 6) in inducing pancreatic differentiation, and
speciﬁcally endocrine differentiation, from the early endoderm. These
effects of endothelium are described in detail in the “Blood vessel and
endothelial-derived factors” section.Fig. 6. Blood vessels are thought to be inductive of pancreatic differentiation. (A) Schemat
evagination from the endoderm. (B) The pdx1-positive cells (blue) can be seen ventrally in
positive cells are in proximity to the dorsal aortae (a). In addition to pdx1 expression, ins
proximity to the large blood vessel which stains positive for VEGF R2 in (E) (with permissioMesenchyme
After this early dependence on the dorsal aorta, pancreatic
epitheliumthenquickly becomes enveloped inpancreaticmesenchyme,
thus separating the pancreatic epithelium from the dorsal aorta. This
early enveloping dorsal mesenchyme is thought to harbor keyic for the induction of the dorsal (above) and ventral (below) pdx1-positive epithelial
a cross-section of the gut in proximity to the vitelline vein (v). (C) Dorsally the pdx1-
ulin expression is shown by arrowheads in (D), and these insulin-positive cells are in
n, Lammert et al., 2001).
8 G.K. Gittes / Developmental Biology 326 (2009) 4–35permissive and instructive signals for the generation of differentiated
pancreatic cell types, and for proper pancreatic morphogenesis.
Golosow and Grobstein reported the ﬁrst deﬁnitive evidence that the
early pancreatic epithelium is dependent on inductive inﬂuences from
the mesenchyme (Golosow and Grobstein, 1962). They noted that
mesenchymewas necessary for cytodifferentiation and morphogenesis
of the pancreas, and that non-pancreatic sources of mesenchyme could
replace the pancreatic mesenchymal effect. Interestingly, the speciﬁc
source of the non-pancreatic mesenchyme could inﬂuence the type of
pancreatic differentiation. Salivary mesenchyme, for example, induced
almost exclusively acinar differentiation, with little or no endocrine
differentiation. Many of these studies suggested that the mesenchymal
effects were due to diffusible factors since the mesenchymal effects
could occur across a ﬁlter barrier. These studies may have been
confounded by the use of a transﬁlter-system where the ﬁlter pore
sizes were large enough to admit small cellular processes (Kallman and
Grobstein, 1964). A second confounding factor was that the cultured
epitheliawere embedded in clotted rooster plasma and chicken embryo
extract, likely rich in active growth factors. Nevertheless, the basic
observations have passed the test of time.
These early studies showing an inductive role for mesenchyme led
to an extensive search for a presumed “mesenchymal factor” by Rutter
and colleagues. Beyond the initial protein biochemical characterization
(Ronzio and Rutter, 1973), and the ﬁnding that a mesenchymal factor
was able to induce differentiation when in physical contact with the
pancreatic epithelial cells (Levine et al., 1973), further pursuit of this
“mesenchymal factor” seemed to reach a dead end. Heterologous tissue
recombination experiments showed that pancreatic mesenchyme
could induce endocrine cells to form from non-pancreatic embryonic
foregut epithelial cells (Kramer et al., 1987) or from allantoic cells (Stein
and Andrew, 1989). Mesenchyme was found to be critical for acinar
development, and in the presence of basement membrane, in lieu of
mesenchyme, ducts would develop (Gittes et al., 1996). Furthermore,
the absence or depletion of mesenchyme revealed that there was aFig. 7. The pancreatic mesenchyme is an important regulator of the differentiation of the pan
of the mesenchyme. (A) H&E staining of a co-culture of E10 mesenchyme with E11 epithelium
of the sample in (A), here the younger mesenchyme induces a more immature epithelia
mesenchyme is recombined with the same E11 epithelium, then instead there is evidence
mesenchyme (m). In addition, in (E) there is an abundance of insulin-positive staining, sugg
endocrine development only in the region of the epithelium that is not in contact with the“default” differentiation of pancreatic epithelium toward islets (Gittes
et al., 1996); (Miralles et al., 1998b). Further studies revealed that the
age and location of themesenchyme had a primary role in determining
pancreatic epithelial fate (Rose et al., 1999) (see Fig. 7). Li et al. then
showed that there were several separable components to the
mesenchymal effect (Li et al., 2004). Proximity or contact of epithelial
cells to mesenchyme led to exclusively acinar/exocrine differentiation.
Absence of proximity/contact of mesenchyme with the pancreatic
epithelium led to exclusively endocrine differentiation. Interestingly,
the presence of mesenchyme, but in the absence of proximity or
contact, led to enhanced insulin differentiation over glucagon or other
non-insulin cell differentiation. Together these results suggested that
there was a pro-exocrine factor in mesenchyme that was cell contact-
mediated, and then an additional, diffusible pro-endocrine/pro-insulin
factor was secreted by the mesenchyme.
Along similar lines, Raphael Scharfmann's group recently showed
that proteoglycans (glypicans and syndecan) and the proteoglycan-
producing enzyme heparan sulfateα-sulfotransferasewere elevated in
the E13.5 rat pancreas, and were localized to the epithelial–mesen-
chymal interface. Inhibition of the sulfation of these proteoglycans
blocked mesenchyme-induced exocrine differentiation (Zertal-Zidani
et al., 2007). Other studies from Scharfmann's laboratory have further
delved into the multiple effects of mesenchyme on lineage selection. It
appears that contact of mesenchyme with epithelium may both
enhance notch signaling-induced hairy enhancer of split 1 (hes1)
expression and inhibit neurogenin 3 expression (see below in the
“Notch signaling” section) to suppress endocrine differentiation
(Duvillie et al., 2006). They found a diffusible factor in mesenchyme
that prevented maturation of β-cells from endocrine-committed
progenitor cells. This latter result would seem to be at odds with the
initial observations above by Rose and by Li. Interestingly, in the follow-
up paper from Scharfmann's group, they found that the observed
enhancement of endocrine differentiation in other studies was likely
explained by the ability of mesenchyme to expand the pool of pdx1-creatic epithelium, and its effects depend on contact with the epithelium and on the age
, showing a lack of exocrine architecture. (B) Glucagon staining and (C) insulin staining
l phenotype with abundant glucagon and little insulin. In contrast, when older, E12
of exocrine structures (arrows) in the region of contact between the epithelium and
esting a more mature endocrine phenotype of the epithelium, and interestingly there is
mesenchyme (m) (with permission, Rose et al., 1999).
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ngn3-positive cells could form from these progenitor cells (Attali et al.,
2007).
A new and interesting role for pancreatic mesenchyme has
recently been suggested by studies of bapx1, a member of the Nkx
family of transcription factors. This factor is expressed in pancreatic
mesenchyme, and bapx1 null mutant mice had failure of separation of
pancreatic mesenchyme and spleen. The spleen is mesenchyme-
derived and normally arises in immediate proximity to the pancreatic
mesenchyme, possibly from the same early pool of mesenchymal cells.
The failure of separation of pancreatic mesenchyme and spleen in
bapx1 mutant mice interestingly led to formation of gut-like
evaginations from the prepancreatic foregut. Similarly, splenic
mesenchyme placed adjacent to prepancreatic foregut endoderm
also induced gut structures. These results support an instructive role
for pancreatic mesenchyme in diverting foregut epithelium away from
the intestinal lineage, possibly mediated by PTF1a (PTF1a, described in
the “PTF1a” section later, is a transcription factor marker of early
pancreas-committed cells within the foregut) (Asayesh et al., 2006). In
addition to speciﬁcation, the bapx1-expressing mesenchyme, through
secretion of FGF's, is instructive for the leftward lateral growth of the
dorsal pancreatic bud that occurs beginning around E11–12 in mice
(Hecksher-Sorensen et al., 2004).
Mesenchymal FGF
Beyond the initial biochemical characterization of a mesenchymal
factor by Rutter and colleagues, more sophisticated molecular
technology available in the last two decades has led to a greatly
improved understanding of the molecules within the mesenchyme
thatmay play an inductive role. Several families of signalingmolecules
have been implicated in regulating mesenchymal–epithelial
interactions.
Fibroblast Growth Factors (FGF's), for example, are well-known to
mediate multiple developmental processes, and have been shown to
be expressed in many epithelial–mesenchymal interface regions, with
a particularly important role in regulating branching morphogenesis
(Reviewed in (Hogan,1999)). They are a large family of ligands (greater
than 20) that signal through multiple different tyrosine kinase FGF
receptors. Scharfmann's group studied the role of FGF's in pancreatic
mesenchyme-to-epithelium signaling in detail. They found that FGF's
1, 7, and 10 were expressed in the pancreatic mesenchyme, whereas
FGF receptor 2B (FGFR2B), a speciﬁc receptor isoform that binds all
three of those FGF ligands, was expressed in pancreatic epithelium.
FGF ligand signaling to FGFR2B induces pancreatic epithelial proli-
feration, both in vitro and in vivo, but at the apparent expense of
cellular differentiation (Elghazi et al., 2002; Celli et al., 1998; Miralles
et al., 1999; LeBras et al., 1998; Le Bras et al., 1998). Similarly, FGF7 and
10 signaling has been implicated in mesenchyme-to-epithelium
signaling in the developing human pancreas (Ye et al., 2005).
Mesenchymal FGF signaling to the epithelium may also speciﬁcally
favor exocrine differentiation. Scharfmann's group found that
exogenous FGF's could enhance the presence of amylase-positive
cells by 20-fold (here it is not clear whether recruitment of progenitor
cells or proliferation of existing progenitor cells is responsible for the
increase). A pro-acinar/exocrine role for FGF was also suggested by
Dichmann et al., wherein a pdx1-FGF4 transgenic mouse (with FGF4
expressed in all early pancreatic epithelial cells) had cystic/ductal
degeneration of the pancreas with persistent acini, but severe
destruction of the endocrine tissue (Dichmann et al., 2003). Here,
there also was an inappropriate proliferation of pancreatic mesen-
chyme, which could confound the interpretation of lineage effects
since mesenchyme enhances exocrine differentiation and suppresses
endocrine differentiation. Similarly, two studies showed that pdx1
promoter driving expression of FGF10 led to enhanced proliferation of
undifferentiated pancreatic epithelial cells, but suppressed endocrinedifferentiation (Norgaard et al., 2003; Hart et al., 2003). Furthermore,
Elghazi et al., added FGF7 to E13.5 pancreatic explant cultures and
found enhanced epithelial growth with suppressed endocrine
differentiation (Elghazi et al., 2002). This effect of exogenous FGF7
was thought to be indicative of an existing active endogenous FGF
signaling pathway, which the authors felt was probably normally
mediated endogenously by FGF10 rather than FGF7. In addition to the
transgenic overexpression data above, Bhushan et al. showed that
FGF10 null mutant mice had blunted branching pancreatic morpho-
genesis and a paucity of pancreatic endocrine cells, possibly due to
inadequate proliferation of endocrine progenitors (Bhushan et al.,
2001). Pulkkinin et al., showed that FGFR2B null mutant mice lacked
the normal early proliferation and branching morphogenesis of the
pancreas (Pulkkinen et al., 2003). However, unlike the FGF10 null
mutants, the FGFR2B null mutant pancreas had normal subsequent
exocrine and endocrine development despite the blunted earlier
epithelial development. Thus, the role of FGF 10 in signaling through
FGFR2b may be to induce proliferation of epithelial cells and to
prevent endocrine differentiation.
The observed effects of FGF's are suggestive of a role for notch
signaling (see “Notch signaling” section). FGF signaling early in
development, likely mediated at least in part by notch signaling
(Hart et al., 2003; Norgaard et al., 2003) and PTF1a expression
(Jacquemin et al., 2006) is necessary to maintain a progenitor
epithelial cell population. Miralles et al. further showed that notch
signaling was a critical mediator of FGF10-induced embryonic
pancreatic epithelial proliferation and suppression of differentiation
(Miralles et al., 2006). Further differentiation of these expanded
progenitor cells into exocrine or endocrine cells may be additionally
modulated by FGF signaling. In FGFR3 null mutant mouse
experiments, for example, different than the role of FGFR2B above,
FGFR3 was found to be necessary for normal suppression of islet
progenitor cell growth and post-natal islet growth, and FGF9 may be
the key ligand here (Arnaud-Dabernat et al., 2007). More recent
studies have suggested that FGF signaling may be important to
speciﬁcation of the pancreatic mesenchyme itself (Manfroid et al.,
2007). Together, all of these studies reﬂect FGFs' role in dorsal
mesenchyme signaling to dorsal pancreatic epithelium. However,
FGF's seem to play an opposite role in ventral pancreas formation,
since FGF's from the cardiogenic mesenchyme on the ventral side of
the foregut actually inhibit ventral pancreas development in favor of
liver development (Deutsch et al., 2001a).
TGF-β signaling
In addition to FGF, many other extracellular signaling pathways
have been implicated in pancreatic development. The TGF-β super-
family represents a large signaling family with roles in nearly every
biological process known, particularly developmental processes. The
superfamily can be divided into four major categories: 1) TGF-β
isoforms proper (including TGF-β 1, 2, and 3 in mammals); 2) activins;
3) BMPs; and 4) other types, including MIS and GDF. These molecules
signal through a large family of typically heterodimeric receptors to
activate smads and other intracellular pathways to initiate speciﬁc cell
responses. The level of signaling modulation is achieved through
various extracellular binding proteins that affect ligand-receptor
interactions.
TGF-β isoforms
Themammalian TGF-β isoforms (TGF-β1, -β2, and -β3) are present
in the embryonic pancreas at least as early as E12.5, localized to the
epithelium. Over mouse gestation, the three TGF-β ligands, which all
seem to co-localize throughout gestation, become progressively
focused to acinar cells (Crisera et al., 1999, 2000b). A key receptor
for these ligands, TGF-β receptor type II (TBR-II) localizes to the
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is speciﬁcally only in the pancreatic ducts, with focal and intense
staining of the ducts by E18.5. Some TBR-II was also seen in developing
blood vessels at this time (Tulachan et al., 2007). TGF-β signaling to
the epithelium early in pancreatic development seems to be
important, but then later signaling to the ducts may be more
important. This signaling occurs through cooperation between TBR-
II and TGF-β receptor type I (TBR-I or Alk5). TBR-I showed a similar
expression pattern to TBR-II in early pancreatic epithelium, and then
later speciﬁcally in ducts. This parallel expression pattern suggests
that TBR-II and TBR-I/Alk5 together mediate TGF-β isoform signaling
in the developing pancreas (Tulachan et al., 2007).
A role for TGF-β signaling in pancreatic lineage selection was
suggested by Sanvito et al., wherein exogenous TGF-β was thought to
enhance endocrine differentiation in the early pancreatic epithelium
(Sanvito et al., 1994). Here, prolonged organ explant cultures were
used, exhibiting acinar autolysis, perhaps due to acinar zymogen
maturation and release, with enzyme activation. Thus, the observed
endocrine enhancement could have reﬂected sparing of the endocrine
cells from autolysis. In an effort to better analyze a possible role for
TGF-β's, two groups created transgenic mice expressing TGF-β1 under
the rat insulin promoter (Sanvito et al., 1995; Lee et al., 1995b). In both
cases the only potential developmental effect was islet disruption into
smaller clusters, with no effect on overall islet mass. This disorganized
islet phenotype is consistent with subsequent studies by Miralles et
al., showing that TGF-β isoforms were important regulators of matrix
metalloproteases that, in turn, appear to control the ability of
endocrine progenitor cells to migrate and coalesce into islets in the
late-gestation embryonic mouse pancreas (Miralles et al., 1998a).
Since TGF-β1/2/3 triple null mutant mice and the TBR-II null
mutant mice are early embryonic lethal, a dominant-negative form of
TBR-II was used to study inhibition of TGF-β isoform signaling. The
adult mice expressing the dominant-negative receptor have ductal
hyperplasia and acinar atypia (Bottinger et al., 1997). Despite the fact
that the MT-1 promoter driving this dominant-negative receptor is
expressed in all organs, the predominant phenotype in the adult
animals is in the pancreas, suggesting that TGF-β isoform signaling is
particularly important in the pancreas. More recent studies have
shown that expression of the dominant-negative form of the TBR-II
receptor in the embryonic pancreas results in an enhanced proli-
feration and accumulation of periductal endocrine cells at mid-to-late
gestation (Tulachan et al., 2007). These data, together with the pattern
of expression of TGF-β ligands and receptors described above, suggest
that TGF-β signaling to ductal progenitors normally serves to restrict
the recruitment of ductal or periductal cells into the endocrine
lineage.
Activins and BMP's
Activin ligands. In addition to the TGF-β isoform sub-family
signaling discussed above, activins and BMP's are two other key
sub-families within the TGF-β superfamily. Activins and BMP's share
many binding partners, receptors, and inhibitors. They participate in
signaling in a large number of developmental processes. Activins have
been found to be expressed in early gut endoderm (Verschueren et al.,
1995; Manova et al., 1995), and are expressed in the early pancreatic
rudiment. Activin A and B localize to the developing pancreatic
endocrine cells, particularly in glucagon-positive cells (Furukawa et
al., 1995;Maldonado et al., 2000). Exogenous activin added to growing
embryonic pancreas explant cultures inhibited branching morpho-
genesis, a process associated with ductal and acinar differentiation
(Ritvos et al., 1995). Inhibition of branching by activin is consistent
with later studies by Miralles et al., in which follistatin, a known
inhibitor of activins that is present in early pancreatic mesenchyme,
was able to replace the pro-exocrine/anti-endocrine effect of
mesenchyme (Miralles et al., 1998b). Demeterco et al., addedexogenous activin A to cultured human fetal pancreas and found a
modest increase in insulin content and insulin-positive cell numbers
(Demeterco et al., 2000). These collective observations support a role
for activin in the early pancreas to enhance endocrine differentiation
and suppress exocrine/acinar differentiation. Slightly later in mouse
development (E12.5), an unusual and unexplained effect of exogenous
activin Awas to induce pancreas explants to form intestine. This effect
was mediated through increased Shh expression and was blocked by
either the hedgehog inhibitor cyclopamine or by the activin inhibitor
follistatin (van Eyll et al., 2004). It remains unknown whether
follistatin has any effect on pancreas development independent of
its ability to inhibit key endogenous TGF-β ligands (follistatin can bind
and inhibit activins and BMP's, and perhaps other TGF-β superfamily
members (Keah and Hearn, 2005)).
There have been some investigations into the mechanisms by
which activin may induce insulin-positive differentiation. Activin can
speciﬁcally decrease expression of Arx (a transcription factor critical
for α-cell differentiation) and pre-proglucagon in a pancreatic duct-
like progenitor cell line (AR42J cells), a glucagon-expressingα-cell line
(α-TC cells), and in human islets (Mamin and Philippe, 2007). Also,
activin seems to induce the neuroendocrine phenotype in AR42J cells
directly through induced expression of neurogenin3 (ngn3), a key
determinant of pancreatic endocrine lineage selection, growth, and
differentiation (see “Neurogenin3 (ngn3) and its targets” section)
(Zhang et al., 2001). This activin-induced ngn3 expression occurs
through an activin A/HGF response element in the ngn3 gene. This
response element is not inﬂuenced by canonical activin signaling since
overexpression of smad7, an inhibitor of canonical activin down-
stream signaling (smads 2 and 3), had no effect on ngn3 expression.
Instead, ngn3 expression here was induced by the non-canonical
target of activin, p38 MAPK (Ogihara et al., 2003). Earlier studies had
suggested that activin A-induced smad2 was necessary for apoptosis
and phenotypic changes in AR42J cells, so clariﬁcation of the exact
downstream activin A mechanisms in these cell lines is still lacking
(Zhang et al., 1999).
Activin receptors. Several studies have addressed the role of
endogenous activin signaling in pancreas development. As mentioned
above, the complexity of activin ligand and receptor signaling makes
this area difﬁcult to study. Loss-of-function activin studies using
transgenic expression of a dominant-negative activin receptor II
under either a global β-actin promoter or the β-cell-speciﬁc human
insulin promoter, both led to islet hypoplasia (Shiozaki et al., 1999;
Yamaoka et al., 1998). If, instead of a dominant-negative activin
receptor, a constitutively-active activin RII was inserted under the
same human insulin promoter, surprisingly a similar islet hypoplasia
phenotype was seen. These results suggest that a speciﬁc window of
activin receptor II signal dosing is necessary for proper islet
development.
Since the dominant-negative activin receptor type II can bindmany
potential TGF-β superfamily ligands, a key subsequent study analyzed
activin-receptor type IIA and/or activin receptor type IIB null mutant
mice (Kim et al., 2000). Both receptors are expressed in the pancreatic
anlage, but the activin receptor type IIA null mutant mouse had no
pancreatic abnormalities (nor did the activin receptor type IIB
heterozygous mutants). Activin receptor type IIB null mutants,
especially if there was an additional activin receptor type IIA
heterozygous mutation, were born with a small pancreas that tended
to partially wrap around the intestine, perhaps as a forme fruste of
annular pancreas. This annular pancreas phenotype may relate to
altered Indian hedgehog signaling in these mice (Hebrok et al., 1998)
(see “Hedgehog signaling” section). Interestingly, notochord-derived
activin signaling inhibits sonic hedgehog expression in the pre-
pancreatic endoderm (see “Notochord” section), and in these activin
receptor type II mutants, inappropriate sonic hedgehog overexpression
was seen.
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mutants with the additional activin receptor type IIA heterozygous
mutation (double-null mutants die prior to gastrulation) revealed
mainly a reduction in endocrine cells, not exocrine cells at E13.5. Later
in gestation, the islets were found to be hypoplastic. Thus, regardless
of the ligand that may be involved, the activin receptor type II family
seems to be important for pancreatic morphogenesis and speciﬁcally
endocrine and islet development.
GDF 11. In an effort to demonstrate the key ligands in the
developing pancreas that may normally induce the activin receptor
type II-mediated effects, Growth Differentiation Factor 11 (GDF11, also
called BMP11 and a TGF-β superfamily member that binds activin
receptor type IIA and B) was identiﬁed as a possible ligand that may
promote β-cell differentiation by endocrine progenitors. Two separate
studies showed slightly different results with GDF11 null mutant mice
(Harmon et al., 2004; Dichmann et al., 2006) (see Fig. 8). Harmon et al.
showed that GDF11 is expressed in embryonic pancreatic epithelium
diffusely from E11.5 to E13.5, and then becomes focused to acinar cells
by E18.5. Here the GDF11 null mutant mouse developmental
phenotype was thought to be similar to that of the activin receptor
type IIB mutants described above, supporting GDF11 as the ligand
acting through activin-receptor type IIB. The pancreas of GDF11 null
mutant mice developed with more ngn3-positive endocrine progeni-
tor cells, less mature insulin-positive β-cells, and more glucagon-
positiveα-cells. Thus, GDF11may be a key TGF-β superfamilymember
regulating formation of the ngn3-positive cells, possibly by affecting
HNF6 expression, a known regulator of ngn3 expression (Jacquemin et
al., 2000). In addition, GDF11 may then promote ngn3-positive cells to
form β-cells rather than α-cells, possibly through enhanced mafA
expression in insulin-lineage-committed Nkx6.1-positive cells (see
“Transcription factors” section) (Smart et al., 2006). GDF11 has been
shown to work through the intracellular mediator smad2, and
consistent with the phenotype of the GDF11 mutants, heterozygous
smad2 mutants showed increased ngn3-positive cells with a sub-
sequent decrease in β-cell mass. These authors made the important
conclusion that smad2 is a critical GDF11/activin receptor type II
intracellular target for β-cell recruitment.
Dichmann et al., found differing results in their GDF11 null mutant
mouse, with an overall 43% reduction in the size of the late-gestationFig. 8. GDF11 null mutant mice develop with an abundance of endocrine progenitor cells. (A,
GDF11 null mutant (B) compared with littermate controls (A) (ductal staining here is identiﬁ
(green) in the mutant mice (D) compared with littermate controls (C) (with permission, Hapancreas, entirely due to loss of acinar cells, with a much greater
acinar loss than in the Harmon study. Numbers of ngn3-positive cells
were still increased, though only doubled, and only late in gestation.
There was no difference in the total number of mature endocrine cells.
Additional experiments were performed to test the dependency of
ngn3-positive cells on GDF11 and activin receptor type IIA and IIB
signaling to form mature endocrine cells. These authors expressed a
dominant-negative Alk-4 (a smad2 activator) in ngn3-expressing
chicken endoderm cells, but again in contrast to the smad2
heterozygous mutant mice in the Harmon study, no effect on
endocrine differentiation was seen. The reason for one study showing
a major role for GDF11 in endocrine development and one not could
be due to differences in genetic strain background, or perhaps due to
the slight differences in the experimental approach.
Consistent with the ﬁnding that smad2 heterozygous mutant
pancreases had a similar phenotype to GDF11 null mutant pancreases,
and that GDF11 is known to signal through the activin receptors,
which signal through smad2 intracellularly, Goto et al. found that
activin receptor IIB signaling through smad2 was important in
promoting endocrine development (Goto et al., 2007).
BMP signaling. Despite the extensive work implicating TGF-β
superfamily signaling in pancreatic development, strikingly little
direct analysis of BMP-speciﬁc pathways in pancreatic development
has occurred. Some role for BMP signaling in pancreatic differentia-
tion is suggested by a few in vitro studies. Exogenous BMP's 4, 5, and 6
are all able to induce dispersed E15.5 mouse pancreatic cells to form
insulin-positive epithelial colonies when grown in the presence of
laminin (Jiang et al., 2001). BMP's are known to be expressed in the
developing pancreas (Dichmann et al., 2003; Jiang and Harrison,
2005; Goulley et al., 2007; Hogan, 1996). In AR42J cells, BMP signaling
was found to be necessary for glucagon-like peptide 1-induced
insulin-positive differentiation (Yew et al., 2005), and also BMP's
promote proliferation of AR42J cells (Hua et al., 2006).
Results from transgenic mice are confusing with regard to roles for
BMP signaling. BMP4 overexpression enhances duct-cell proliferation
in a transgenic model of islet neogenesis (Hua et al., 2006). However, a
pdx1-BMP6 transgenic mouse developed with complete pancreatic
agenesis (Dichmann et al., 2003), a phenotype the authors attributed
to an epiphenomenon of overinduction of intestinal smoothmuscle inB) synaptophysin-positive (SYN) endocrine progenitor cells in greater abundance in the
ed by DBA). (C, D) the development of glucagon cells (red) is favored over insulin cells
rmon et al., 2004).
12 G.K. Gittes / Developmental Biology 326 (2009) 4–35the duodenal anlage, which disrupted pancreatic development.
Conditional deletion of the BMP receptor 1A in insulin-positive cells
did not have an effect on development, though did lead to altered
glucose homeostasis (Goulley et al., 2007). Also, in contrast to the
pdx1-BMP6 study, pdx1-BMP4 mice were born with a normal
pancreas. Transgenically driven BMP inhibitors, noggin or smad6,
under the pdx1 promoter had no embryonic pancreatic phenotype.
Thus, clearly BMP signaling has a potential role in pancreatic
development, but a more precise understanding of that role awaits
further characterization.
Smads
As discussed above, smad molecules appear to play a role in
pancreatic development. They are expressed in neonatal islets (Brorson
et al., 2001), are necessary for both insulin-positive differentiation by
AR42J cells (Zhang et al., 1999; Yew et al., 2005), and for proper
regulation of the endocrine progenitor cell compartment in vivo
(Harmon et al., 2004; Goto et al., 2007). There has been a general
interest in the role of TGF-β superfamily members and smads in
pancreatic development and differentiation because smad4 was
speciﬁcally identiﬁed as mutated in 50% of pancreatic cancers (Hahn
et al., 1996). Studies of smad4 function have not uncovered a key role in
pancreatic development (Simeone et al., 2006; Bardeesy et al., 2006),
though smad4 may play a role in maintaining normal differentiation of
ductal or islet cells. Smad6 is a speciﬁc inhibitor of smads1, 5, and 8; the
canonical downstream mediators of BMP signaling. Smad7 inhibits all
smads including bothBMP-induced smads (smads1, 5, and8) andTGF-β
isoform/activin-mediated smads (smads2 and 3). Interestingly, when
smad7 was expressed under the pdx1 promoter in transgenic mice,
there was a dramatic (85–90%) reduction in the number of β-cells
present at birth (Smart et al., 2006). Asmentioned above, a pdx1-smad6Fig. 9. Notch signaling activation leads to premature commitment to the endocrine lineage.
littermates (A). In delta-like 1 nullmutants (D and F), there is premature andhigher expression
littermates (C and E) (with permission, Apelqvist et al., 1999).transgenic mouse did not have a developmental phenotype. Thus,
together these results suggest that smad2 and 3 may be the key smad
mediators of β-cell differentiation. Additionally, the β-cell loss with
smad7 expression seems to be replaced by the formation of glucagon
cells, suggesting a possible role for smads2 and 3 in regulating the
balance between the formation of β-cells and α-cells.
Notch signaling
Because of the well-established parallels between pancreatic
endocrine development and neuronal development, the notch-signal-
ing pathway, a regulator of neuronal differentiation in Drosophila, was
studied in pancreatic development. Notch is a cell membrane-bound
receptor that serves to maintain cells in an undifferentiated state when
bound by notch ligands such as jagged, serrate, or delta-like molecules.
A landmark paper from the Edlund laboratory demonstrated that notch
signalingwas a keymediator of fate decision inpancreatic development
(Apelqvist et al., 1999) (see Fig. 9). Null mutant mice for either a key
notch ligand present in the developing pancreas, delta-like 1, or for the
transcription factor RBP-Jk (a target of notch signaling), both resulted in
an accelerated and over-abundant commitment of the early embryonic
pancreatic epithelium to the endocrine lineage, suggesting that notch
signaling was necessary to prevent endocrine differentiation by these
progenitor cells. This study also showed that forced overexpression of
ngn3 (which normally is suppressed by notch signaling and is an
important pancreatic pro-endocrine transcription factor, see “Neuro-
genin3 (ngn3) and its targets” section for more details), led to a similar
“endocrine-only” phenotype. No clear “lateral inhibition” parallel has
been established in the pancreas with respect to notch ligand/receptor
signaling, as was demonstrated in Drosophila. Subsequent studies by
Schwitzgebel et al. conﬁrmed that pdx1-ngn3 forced expression led to
the development of mainly glucagon cells, with very few insulin-(A, B) In RBP-Jκ mutants (B) ngn3 is expressed early and in more cells than in wild-type
of ngn3andneuroD in cells committed to the endocrine lineage, comparedwithwild-type
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that additional signals beyond simple notch-versus-ngn3 are necessary
to determine insulin-cell development. Such additional pro-β-cell
signals may rest with the recently reported pro-insulin effects of
mesenchyme (Li et al., 2004; Duvillie et al., 2006; Attali et al., 2007), and
perhaps with GDF11 signaling (see GDF11 section). Beyond the initial
endocrine-versus-exocrine lineage decision, Notch signalingwas found
to also play a role in growth and branching of the undifferentiated
pancreatic epithelium.
Further studies have conﬁrmed a key role in pancreatic develop-
ment for other members of the notch signaling pathway. Hairy
enhancer of split 1 (hes1) is upregulated by notch and responsible for
ngn3 suppression. Hes1 null mutant mice have severe pancreatic
hypoplasia (Jensen et al., 2000c); this hypoplasia was not apoptotic,
but was instead due to an inappropriate early commitment of
precursor cells to becoming endocrine cells. Notch signaling was
further implicated in pancreatic speciﬁcation of endoderm, since the
hepatic/biliary ﬁeld and intestinal ﬁeld of the endoderm had ectopic
pancreas in notch signaling mutants (see below). Notch receptors and
ligands are expressed in the developing pancreas well beyond the
initial lineage selection period (Lammert et al., 2003; Yoshida et al.,
2003). Acinar cell formation, which occurs through branching
morphogenesis of the early epithelium followed by acinar cell
differentiation, has been shown to be regulated by notch signaling
(Hald et al., 2003). Overdriving notch signaling using transgenic
expression of an active intracellular domain of notch under the pdx1
promoter led to the absence of signiﬁcant numbers of mature
endocrine or acinar cells (similar to the FGF overexpression mice
described above), suggesting that active notch signaling, perhaps
acting downstream of FGF's, may select for a progenitor epithelial cell
population (Murtaugh et al., 2003). Importantly, using tamoxifen-
regulatable promoters, delayed activation of notch signaling until E13
to E15 still led to the absence of acinar cells, with persistence of
epithelial progenitor cells, implying that even if notch was induced in
pdx1-positive epithelial cells later in gestation, perhaps even after the
epithelial cells had initiated a differentiation program, those cells
could still be reverted to progenitor-like cells (Murtaugh et al., 2003).
The mechanism for this role of notch signaling in preventing acinar
differentiation may be through inhibition of PTF1a, a transcription
factor that can activate an acinar cell repertoire of genes, and that is
associatedwith acinar differentiation (Esni et al., 2004). Ngn3-positive
cells, which represent immature and still proliferative endocrine
progenitor cells, could be reverted to a duct-like progenitor-cell
phenotype (Murtaugh et al., 2003). However, driving notch in mature
pancreatic endocrine cells could not revert them to a progenitor state
(Murtaugh et al., 2003; Fujikura et al., 2006), so notch effects seem to
require a relatively undifferentiated cell in order to induce effects.
Along similar lines, regeneration of islet cells from pre-existing
differentiated cells after partial pancreatectomy does not involve an
ngn3-protein-positive state and, therefore, may represent a notch-
independent way of forming new endocrine cells (Lee et al., 2006).
Recent evidence suggests that post-pancreatectomy islets have high
levels of ngn3 mRNA, but mRNA translation to protein is suppressed
by micro RNA's (see “Micro RNA” section) (Joglekar et al., 2007).
The mechanism by which notch maintains the proliferation of a
stem/progenitor pool in the pancreatic epitheliummost likely involves
mesenchymal FGF signaling. As discussed earlier, mesenchymal FGF's
appear to play an important role in mediating mesenchyme-to-
epithelium signaling. FGF signaling to promote expansion of an
epithelial progenitor pool requires active notch signaling through
Hes1 (Miralles et al., 2006; Norgaard et al., 2003). Furthermore, Hes1
normally downregulates p57, a key cyclin kinase inhibitor, to allow
expansion of these pancreatic progenitor cells (Georgia et al., 2006).
The exact role of notch signaling in pancreatic lineage selection
remains complex. Clearly, early notch signaling favors non-endocrine
lineages over endocrine lineages, and is critically mediated by Hes1inhibition of ngn3. The control point for notch receptor function may
be enzymes that regulate sugar residues on the notch receptor. In
zebraﬁsh, the enzyme manic fringe can alter notch receptor function
and drive premature ngn3-positive expression and endocrine
differentiation (Xu et al., 2006). Thus, in order for a progenitor cell
to become an ngn3-positive endocrine-committed progenitor, notch
receptor modiﬁcation may be necessary. Further zebraﬁsh analyses
showed that later in gestation notch signaling can affect lineage
selection within the endocrine compartment. For example, deltaA
mutants (a notch ligand) showed a shift away fromα-cells and toward
β-cells, and jagged 1Bmutants hadmore α-cells, with no change in β-
cell numbers (Zecchin et al., 2007).
One reason for the complexity of notch signaling in pancreatic
development lies in the key downstream transcription factor, RBP-J,
which mediates signaling by all of the notch receptors. Recently,
another key pancreatic regulatory transcription factor, PTF1a, has
been found to have complex interactions with RBP-J. PTF1a is part of a
heterotrimeric transcriptional complex, PTF1 that was originally
described as a ubiquitous acinar enzyme gene regulator (Petrucco et
al., 1990). Subsequently, the basic helix–loop–helix moiety of PTF1,
called PTF1a or p48 was found to be present early in embryonic
pancreas. p48/PTF1a null mutant mice developed with no pancreatic
bud, but had the fascinating phenotype of islets developing in the
spleen, derived from prepancreatic endodermal cells that had
migrated out of the epithelium and into the overlying pre-splenic
mesoderm (see Fig. 12 and “PTF1a” section). These two separate roles
for PTF1a, in the early embryonic pancreas and then later in gestation,
corresponds with to two different functions of RBP-J. RBP-J has two
paralogs, RBP-Jκ and RBP-Jl. Both molecules can bind PTF1a, but only
the “κ” form can mediate notch signaling (Beres et al., 2006). PTF1a
determines pancreatic development in the endoderm, and in Hes1
null mutant mice the resulting PTF1a overexpression induces
pancreas formation in ectopic sites, such as intestine and liver
(Sumazaki et al., 2004; Fukuda et al., 2006). These PTF1a-integrated
functions of notch seem to require RBP-Jκ interaction with PTF1a
(Masui et al., 2007). As pancreatic development progresses, and acinar
cells begin to form, which is presumably dependent on PTF1a (Esni et
al., 2004) and on notch repression, the PTF1a-RBP-Jκ complex begins
to activate expression of the “l” form. RBP-Jl expression then becomes
ampliﬁed, and competes for PTF1a binding with RBP-Jκ, resulting in a
displacement of RBP-Jκ by RBP-Jl. Consistent with the fact that RBP-Jl
is present in maturing acinar cells, RBP-Jl is not notch-dependent, and
RBP-Jl is the paralog that participates with PTF1a in the PTF1
heterotrimer complex that regulates mature acinar enzyme gene
expression. Thus, PTF1a and notch signaling create a complex
interactive program to regulate pancreatic ﬁeld commitment,
endocrine-versus-endocrine lineage commitment, and acinar cell
maturation and function.
Lastly, notch appears to play a potential positive role in duct
formation (Greenwood et al., 2007). Such a role was suggested by the
fact that notch mutants lack cells positive for duct markers (Lorent et
al., 2004; Yee et al., 2005). Pax4 is a marker of committed endocrine
cells downstream of ngn3. Driving notch activity through transgenic
expression of the notch intracellular domain peptide in pax4-positive
cell lineages led to more pancreatic ducts, representing the only clear
positive data for a role for notch signaling in duct formation
(Greenwood et al., 2007).
Hedgehog signaling
Like notch signaling, the hedgehog signaling pathway regulates
differentiation in many developing tissues. The three hedgehog
ligands, Sonic, Desert, and Indian, all bind to a patched (ptc) receptor.
Ligand binding relieves ptc-induced repression of membrane-bound
smoothened, which then in turn regulates the Gli family of transcrip-
tion factors. Hedgehog signaling is controlled through: 1) the
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binding of ligand by hedgehog interacting protein (Hhip) in a
dominant-negative receptor fashion; and 3) sequestering ligand on
the ptc receptor.
In the early embryo Sonic hedgehog (Shh) is expressed in almost
the entire gut epithelium. However, Shh expression is inhibited in the
pancreatic domain of the foregut as a prerequisite to pancreas
formation. Nearby notochord has a Shh-suppressive effect on the
endoderm in the region of the pancreas, and notochord co-cultured
with endoderm rescued pancreas differentiation, as did Shh inhibitory
antibodies (see “Notochord” section) (Hebrok et al., 1998). Similarly
cyclopamine, which inhibits Shh signaling in target tissues at the level
of the smoothened receptor, could induce heterotopic pancreas
formation, presumably by expanding the pancreatic ﬁeld in the gut,
but only into pdx1-positive ﬁelds (stomach and duodenum). The
notochord effect may be through the release of activins, which are Shh
inhibitors (Hebrok et al., 1998). Such a role for activins would explain
the expanded Shh expression and decreased pancreas formation seen
in activin receptor mutants (Kim et al., 2000). Simple deletion of Shh
does not actually lead to an expanded pancreatic ﬁeld, but the relative
size of the pancreatic ﬁeld is increased since the size of the pancreas is
preserved, despite the embryo being smaller (Hebrok et al., 2000).
While Shh inhibition by the notochord controls formation of the
dorsal pancreatic ﬁeld in the endoderm, the notochord does not
control formation of the ventral pancreas. The inductive counterpart
to the notochord for the ventral pancreas is the cardiogenic
mesenchyme, which is known to regulate pancreatic development
through FGFs (Deutsch et al., 2001a), which in turn regulate Shh
expression. One of Shh's roles in the non-pancreatic endoderm is to
induce the overlying mesenchyme (which expresses the ptc receptor)
to undergo intestinal smooth muscle differentiation (Apelqvist et al.,
1997). In the pancreatic ﬁeld of the endoderm, however, where Shh is
normally absent, the mesenchyme begins to involute by E15. This
mesenchymal involution explains why, unlike the intestine, the
mature pancreas has no overlying smooth muscle, and no external
coverage at all.
The contradiction of a lack of an expanded pancreatic ﬁeld in Shh
null mutants, but the presence of an expanded pancreatic ﬁeld
(ectopic pancreas) in cyclopamine-treated (Shh-inhibited) endoderm
could be explained by cyclopamine blocking other (non-Sonic)
hedgehogs. Indian hedgehog (Ihh) and Desert hedgehog, and the
receptor ptc are expressed in the foregut and pancreas (Hebrok et al.,
2000; Thomas et al., 2000), and Ihh null mutants are bornwith a small
pancreas (Hebrok et al., 2000), suggesting a direct pro-pancreatic role
for Ihh. Further support for a role of Ihh, particularly in ventral
pancreas formation, is that when a Shh null mutation is combined
with a heterozygous Ihh mutation an annular pancreas develops
(annular pancreas is a malformation in which the ventral pancreas-
derived “head” of the pancreas encircles the duodenum).
Ptc null mutant embryos, which have constitutive hedgehog
signaling due to the loss of ptc as a smoothened repressor, lack pdx1
and glucagon expression in the pancreas at E9.5, further supporting
the need for Shh suppression to allow proper early pancreas formation
(Hebrok et al., 2000). A similar hedgehog signaling overactivity is seen
in Hhip mutants (Hhip is the decoy receptor that acts to inhibit
hedgehog signaling). These mice develop with a smaller pancreas and
fewer islets. Mice with a combined Hhip null mutation and a
heterozygous ptc mutation, which would presumably lead to even
higher levels of hedgehog signaling, had severe pancreatic hypoplasia
(Kawahira et al., 2003). Little data currently exists regarding the
potential role of hedgehog signaling in later gestation pancreas.
Transgenic expression of Shh or Ihh under the pax4 promoter, with
over-expression in the epithelium beginning at E12.5 (Smith et al.,
2000), led to a dramatic loss of endocrine and exocrine tissue, but with
a large amount of mesenchyme/stroma. These results suggest a role
for hedgehog suppression in maintaining proper pancreatic develop-ment beyond early development (Kawahira et al., 2005). Later, in
mature β-cells, which express ptc, Shh upregulates pdx1 expression
and function and, therefore, insulin expression (Thomas et al., 2001b,
2000). The true complexity of hedgehog signaling and pancreatic
development is further underscored by the fact that in zebraﬁsh
embryos, instead of inhibiting pancreatic development, hedgehog
signaling is actually necessary for pancreatic endocrine cells to form
(Roy et al., 2001; diIorio et al., 2002, 2007).
Retinoids
Retinoid signaling plays an important role in numerous develop-
mental processes. Several studies have suggested a role for retinoid
signaling in the developing pancreas. In support of a role for retinoid
signaling in endocrine differentiation, retinoid binding proteins and
retinoic acid receptors have been found in developing pancreatic islets
and in insulinoma cell lines (Tulachan et al., 2003; Martin et al., 2005;
Kato et al., 1985; Chertow et al., 1979, 1983; Kobayashi et al., 2002;
Stafford et al., 2006), and exogenous retinoids are able to enhance the
proportion of insulin-positive cells in isolated chick embryo
endoderm (compared with the proportion of glucagon-positive
cells). Beyond these effects of retinoids on endocrine cells, retinoids
can induce the dorsal lip cells of Xenopus gastrulae to form endocrine
and acinar pancreatic elements (Moriya et al., 2000b, 2000a). In the
embryonic mouse pancreas, retinoids were found to induce endocrine
and ductal differentiation (Tulachan et al., 2003; Shen et al., 2007), as
well as inﬂuence the later decision between ductal and acinar/
exocrine differentiation (Kobayashi et al., 2002). These latter effects
appear to be mediated through epithelial–mesenchymal interactions.
Much of the recent work on the role of retinoid signaling in
pancreatic development has come from zebraﬁsh studies. RALDH2 is
an enzyme that produces retinoic acid and is present in the
developing pancreas, speciﬁcally in the mesenchyme (Tulachan et
al., 2003; Martin et al., 2005; Molotkov et al., 2005; Stafford et al.,
2006). In zebraﬁsh, mesoderm-derived retinoic acid signals to the
endoderm (Martin et al., 2005; Stafford et al., 2006) to induce
pancreatic differentiation. Using RALDH2mutant strains and injection
of dominant-negative retinoic acid receptor constructs, endogenous
retinoic acid signaling was found to be necessary for endocrine
pancreatic formation in zebraﬁsh, and for the formation of the entire
pancreas in Xenopus and quail (Stafford et al., 2004; Chen et al., 2004;
Kumar et al., 2003; Stafford and Prince, 2002). These effects on
pancreatic lineages appear to be due to loss of pancreatic ﬁeld
speciﬁcation within the endoderm. Conversely, exogenous retinoic
acid could actually expand the pancreatic ﬁeld (Stafford and Prince,
2002; Stafford et al., 2004; Chen et al., 2004). Beyond deﬁning the
pancreatic ﬁeld within endoderm, mesenchymal retinoic acid in
zebraﬁsh speciﬁcally signals to endoderm to induce insulin-positive
differentiation, and constitutive retinoic acid receptor activity in
endoderm cells was instructive for insulin-positive differentiation
(Stafford et al., 2006). Thus, a clear and important role for retinoid
signaling has been established for multiple aspects of zebraﬁsh
pancreatic development.
These non-mammalian animal studies correlate fairly well with
mouse data. RALDH2 null mutant mice lack a dorsal pancreas, but the
role of RALDH2 production of retinoic acid in mammalian ventral
pancreas is less clear (Martin et al., 2005; Molotkov et al., 2005).
RALDH2 is present in both dorsal mesenchyme and lateral plate
mesoderm, but by using a retinoic acid-responsive reporter to
demonstrate cells with active retinoid signaling, most retinoic acid
responding cells were found in the dorsal pancreatic bud (including
some insulin and glucagon-positive cells), but not in ventral pancreas.
Also, in contrast to the non-mammalian studies, a RALDH2 mutation
may not affect the pancreatic ﬁeld within the endoderm since Sonic
hedgehog suppression still occurs properly (although little pdx1 and
PTF1a was seen in this RALDH2 deﬁcient prepancreatic endoderm).
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E12.5, suggesting a diminished role for retinoids in later stages of
pancreatic development. Thus, while retinoid signaling clearly plays
an important role in pancreatic development, the varied ﬁndings
between different species and at different points in gestation under-
score the likely complexity of the mechanisms by which retinoids act.
Epidermal growth factor (EGF) family
The EGF family of growth factors consists of at least 30 member-
ligands that signal through at least 4 ErbB tyrosine kinase receptors.
Two paired articles in 1990 showed that transgenic mice with diffuse
overexpression of TGF-α, an EGF-family member, under a metallothio-
nein promoter had severe pancreatic ﬁbrosis (Jhappan et al., 1990;
Sandgren et al., 1990). The overall complexity of EGF-family signaling
has made understanding its role in pancreatic development difﬁcult.
Numerous studies of the spatiotemporal expression of EGF-family
ligands and receptors have been performed. HB-EGF is a membrane-
bound ligand that can be cleaved by metalloproteases into a diffusible
active molecule. It is expressed in early embryonic pancreatic ducts
and later in neonatal islets (Kaneto et al., 1997). HB-EGF was of interest
since it was predominantly co-localized with pdx1, and its promoter
elements were bound and activated by pdx1. However, a pdx1-HB-EGF
transgenic mouse had minimal developmental changes, despite the
use of a 4.6 kb pdx1 promoter element, which confers early embryonic
pancreatic expression. These mice did have islets with glucagon-
expressing cells dispersed throughout the islet instead of the normal
peripheral glucagon-cell location (Means et al., 2003), suggesting a role
for HB-EGF in islet architecture. Many other EGF ligands are present in
the embryonic pancreas (Huotari et al., 2002).
Many studies have used exogenous EGF ligands to manipulate
pancreatic development and to induce β-cell formation. Betacellulin is
an EGF family member that was initially isolated from a β-cell tumor
(Shing et al., 1993). At E11.5 it is expressed in the pancreatic epithelium
(Thowfeequ et al., 2007).Whenbetacellulin andactivinAwere added to
AR42J cells 100% of the cells became insulin-positive (Mashima et al.,
1996a). Betacellulinwas also able to induce proliferation of undifferen-
tiated epithelial cells in human fetal pancreas, andwhen used together
with activin A, islet-like cell clusters formed (Demeterco et al., 2000).
Similarly, in E11.5 mouse pancreas cultures, betacellulin was able to
expand a pdx1-positive population of epithelial cells and induce
insulin-positive differentiation at the expense of acinar differentiation
(Thowfeequ et al., 2007). Thus betacellulin appears to be an important
potential inducer of β-cell formation. This important insulinogenic
effect is speciﬁcally mediated by the receptor ErbB1, since ErbB1 null
mutant embryonic pancreas was resistant to any betacellulin-induced
insulinogenic effect. However, a true endogenous role for betacellulin in
pancreatic development remains elusive since betacellulin null mutant
mice develop with a normal pancreas (Jackson et al., 2003), and
betacellulin neutralizing antibody has no effect on insulin-positive
differentiation in cultured pancreas (Huotari et al., 2002).
EGF itself is known to be an important regulator of many
epithelial–mesenchymal interactions (Warburton et al., 1992), and
early studies showed that exogenous EGF could induce duct develop-
ment in cultured embryonic pancreas (Sanvito et al., 1994). Similarly,
Scharfmann's group showed that exogenous EGF could enhance
proliferation of undifferentiated epithelial cells. Interestingly, these
expanded undifferentiated cells could subsequently be channeled to
endocrine differentiation by removal of the EGF (Cras-Meneur et al.,
2001). Whether these effects of EGF represent true endogenous
mesenchyme-to-epithelium signaling remains to be determined.
EGF receptors
Beyond the complexity of the EGF ligands, most of the signals are
then transduced by one of a family of four tyrosine kinase-containingErbB receptors (ErbB1 through 4). The importance of ErbB1 (the
original EGF receptor, which is expressed throughout the embryonic
mouse pancreas) was shown in a null mutant mouse that had
diminished development of endocrine cells, with an overall smaller
pancreas, perhaps due to decreased branching morphogenesis
(Miettinen et al., 2000). More recently, a transgenic mouse with
pancreas speciﬁc (pdx1 promoter) expression of a dominant-negative
form of the ErbB1 receptor was able to survive beyond the neonatal
period, but had loss of post-natal β-cell proliferation, supporting an
endogenous role for EGF receptors in not only prenatal, but also post-
natal β-cell growth (Miettinen et al., 2000, 2006). In addition to ErbB1,
ErbB4 is expressed throughout the pancreatic epithelium at E12.5, and
then becomes restricted to ducts by E16.5 (Kritzik et al., 2000). ErbB4
was speciﬁcally important in δ-cell development since neutralizing
antibodies against NRG4, an EGF family ligand that only binds ErbB4,
speciﬁcally blocked δ-cell development (Huotari et al., 2002). Further
analysis of ErbB2–4 function awaits conditional mutants, since all
three null mutants are early embryonic lethal (Gassmann et al., 1995;
Lee et al., 1995a; Erickson et al., 1997).
Hepatocyte growth factor (HGF)
Signiﬁcant evidence has accumulated supporting an endogenous
role for HGF in inducing β-cell formation. HGF and its receptor c-met
were found to be expressed in E13mouse pancreatic mesenchyme and
epithelium, respectively (Sonnenberg et al., 1993). Also, human
pancreatic fetal ﬁbroblasts, which develop from early embryonic
mesenchyme, express high levels of HGF, and c-met is expressed in
developing human fetal β-cells. Interestingly, conditioned medium
from human pancreatic fetal ﬁbroblasts was able to induce β-cell
proliferation and the formation of islet-like cell clusters. This effect
was speciﬁcally blocked by HGF neutralizing antibodies (Otonkoski et
al., 1994, 1996). Similarly, exogenous HGF had a pro-β-cell effect on
human fetal pancreas in culture, more so than FGF or TGF-β
(Otonkoski et al., 1994). HGF is similar to FGF in being an extracellular
matrix-bound growth factor. Consistent with its interaction with
extracellular matrix, HGF's pro-β-cell effect in cultured human
pancreas was greatly enhanced by the presence by matrix molecules
and by cell–cell contact (Beattie et al., 1996).
In an effort to harness the pro-β-cell effects of HGF in vivo, rat
insulin promoter (RIP)-HGF transgenic mice were created, resulting in
an increased number of islets with enhanced insulin content (Garcia-
Ocana et al., 2000). Since β-cells express c-met, two groups created β-
cell speciﬁc c-met ablation using RIP-cre with a ﬂoxed c-met. The islet
size was reduced in one of the two strains, but no other major
developmental effects on islets were seen (Dai et al., 2005; Roccisana
et al., 2005).
Interestingly, a role for HGF signaling to c-met in the regulation of
pancreatic endocrine differentiation was supported by observations in
cell lines. HGF could prevent dexamethasone-induced acinar differen-
tiation of AR42J cells and, when combined with activin A, HGF could
induce insulin-positive differentiation (Mashima et al., 1996b).
Similarly, using a pancreatic cell line resembling ducts (ARIP cells),
HGF alone could stimulate insulin-positive differentiation after 72 h.
Interestingly, these cells recapitulated the canonical pancreatic endo-
crine developmental pathway, with early (6-hour onset) expression of
ngn3 and later (24 h) expression of neuroD (Anastasi et al., 2005). As
evidence of the importance of HGF signaling to endocrine development
in vivo, neonatal pancreaswasdispersed andc-met-positive cells sorted
using anti-c-met antibodies. These c-met positive cells behaved like
multi-potent pancreatic progenitors, forming cell clusters that, when
transplanted in vivo formed pancreatic exocrine and endocrine
elements (Suzuki et al., 2004). Demonstrating a role for HGH/c-met in
pancreatic differentiation will require the functional inactivation of c-
met in pancreatic multipotent progenitors or in pancreatic endocrine
progenitors using conditional knock-out approaches.
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Wnts are a highly complex family of signaling molecules that have
been shown to play a role in multiple aspects of pancreatic
development. The Wnt ligands typically signal through the frizzled
(frz) family of seven-pass transmembrane receptors, together with the
co-receptor LRP 5/6 (lipoprotein-related peptide) to stabilize a key
intracellular factor, β-catenin. Normally, in the absence of Wnt
signaling, β-catenin is phosphorylated by a protein complex containing
axin, APC, and Gsk3β, which leads to ubiquitination and destruction of
β-catenin. β-catenin, independent of Wnt signaling, can stabilize
cadherin interactions with cytoskeletal actin through the adaptor
protein α-catenin. Wnt ligand signaling can be inhibited by the
presence of dickkopf, a secreted frizzled-related peptide (sFrp) that can
bind LRP's and inhibit their activity.Wnt signals are thought tomediate
epithelial–mesenchymal interactions in many developing organs
(Nusse and Varmus, 1992).
A very early role for Wnt signaling in pancreatic speciﬁcation
within the foregut was recently established in Xenopus (McLin et al.,
2007). Absence of Wnt8 in the mesoderm prevented foregut
formation by the endoderm. Ectopic Wnt signaling prevented the
normal formation of foregut from the anterior endoderm, resulting in
the absence of liver and pancreas. This Wnt-induced foregut
inhibition appears to be mediated by β-catenin-induced vent2
expression, a homeodomain-containing transcription factor that
represses Hhex, a key patterning gene for foregut development.
Thus, in normal foregut development the loss of Wnt signaling leads
to destruction of β-catenin, with resulting unrepressed Hhex
expression and formation of liver and pancreas.Fig.10.Multiple studieshave shownalterations inpancreatic developmentbasedon changes in
preservation of insulin and glucagon cells in the knock-out pancreas (A and B vs. A′ and B′), w
cpa1) (C′ compared with C) (with permission, Murtaugh et al., 2005). Similarly, Wells et a
compared with wild-type littermates (E) (with permission, Wells et al., 2007). Heiser et al., s
a massive 4.6-fold enlargement of the pancreas (F) (with permission, Heiser et al., 2006).Beyond early endoderm patterning, the role of Wnt/β-catenin
signaling in pancreatic development is complex and dependent on the
time and place ofWnt signaling. A detailed analysis of Wnt expression
patterns revealed that many Wnts, frz's, LRP5/6, and sFrp's are
expressed in the developing pancreas (Heller et al., 2002). In general,
Wnt ligands tend to be localized to the pancreatic mesenchyme during
early pancreatic development, whereas frz's and sFRP's are in both the
mesenchyme and the epithelium, with some of them localizing
speciﬁcally to endocrine cells. Consistent with the role of Wnts in the
foregut and pancreas speciﬁcation discussed above, pdx1-Wnt1 and
pdx1-Wnt5a transgenic mice had pancreatic agenesis and severe
hypoplasia, respectively, conﬁrming a speciﬁc role of Wnts in
suppressing pancreatic development. Transgenic expression of
wnts2, 4, 6, or 7a had no phenotype.
Beyond these earlyﬁndings byHeller et al., numerous recent reports
attempted to dissect the role of Wnt/β-catenin signaling in pancreatic
development (see Fig. 10). Five separate studies have used various
forms of the pdx1 promoter to conditionally regulate Wnt-β-catenin
signaling in the pancreas. Murtaugh et al., showed that β-catenin
ablation in pdx1-positive pancreatic progenitors speciﬁcally prevented
exocrine development, and slightly reduced proliferation of pdx1-
positive progenitor cells (Murtaugh et al., 2005). Using a similar
strategy, Wells et al., showed a more severe reduction in the
proliferation of pdx1-positive progenitors and a striking loss of
exocrine/acinar tissue (Wells et al., 2007). In this study by Wells et al.,
themicewere bornwith essentially a complete absence of acinar tissue,
butwith a normal complement of fully functional islets. In both of these
studies, the loss of exocrine/acinar tissue seemed to be due to loss of
canonicalWnt signaling, rather than loss of themembrane stabilizationWnt signaling. In a pdx1-speciﬁc knock-out ofβ-catenin,Murtaugh et al., showed relative
hereas there was a dramatic loss speciﬁcally of acinar cells (carboxypeptidase1-positive,
l., showed a dramatic loss of acinar tissue in pdx1-speciﬁc β-catenin knock-outs (D)
howed that hyperfunctioning β-catenin speciﬁcally in pdx1-positive cell progeny led to
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zation of Wnt's to the mesenchyme (Heller et al., 2002), together with
the exocrine/acinar-speciﬁc effect of β-catenin ablation are in linewith
the known mesenchyme dependence of exocrine/acinar growth and
differentiation. Some of these conditional β-catenin mutant mice still
developed acinar tissue, but the acinar cells were allβ-catenin-positive,
suggesting a mosaic cre expression allowing growth of some acinar
cells through “escape” β-catenin expression.
The complexity of pdx1 promoter-driven studies ofWnt signaling is
best illustrated by studies from the Hebrok laboratory in which an
early-expressingpdx1-cre (pdx1early), a late-expressing pdx1-cre, and a
tamoxifen-regulatable pdx1-cre were all used to conditionally express
a constitutively active stabilized β-catenin (stabilized due to excision of
the exon 3 phosphorylation site). Early production of the constitutively
active β-catenin, in either pdx1early-cre transgenics, or tamoxifen
treatment of the pdx-cre-ER embryos at E11.5, led to near-total
pancreatic hypoplasia due to overactive Wnt signaling (Heiser et al.,
2006). These results are consistent with the above ﬁndings by Heller et
al. with the pdx1-Wnt1a/5a transgenic animals in which premature
Wnt signaling blocks pancreatic development. Hebrok's group further
found an absence of FGF10 and high levels of Shh at E10.5 in the
pdx1early-cre promotermice. This absent FGF10/high Shh could explain
the pancreatic hypoplasia since FGF10 null mutant mice or pdx1-Shh
transgenic mice both have pancreatic agenesis (Bhushan et al., 2001;
Ahlgren et al., 1997).
While overactiveWnt signalingmay give rise to pancreatic agenesis
or hypoplasia affecting both endocrine and exocrine development
(Heiser et al., 2006;Heller et al., 2002), Papadopoulou andEdlund found
that a soluble frz protein, which broadly inhibits Wnt ligands, when
expressed under a pdx1 promoter in transgenic mice, led to severely
decreased numbers of proliferating epithelial progenitor cells, and
eventual pancreatic hypoplasia affecting both exocrine and endocrine
development (Papadopoulou and Edlund, 2005). These results suggest
that some Wnt signaling may affect exocrine development, whereas
other Wnt signaling may affect endocrine growth and development.
With either the “late”-expressing pdx1-cre, or else late tamoxifen
treatment of tamoxifen-inducible pdx1-cre-ER embryos, no effect on
embryonic pancreatic development was seen.
A ﬁfth study, by Dessimoz et al. yielded results that did not agree
with the above four studies (Dessimoz et al., 2005). Using a pdx1-cre
promoter to conditionally inactivate β-catenin, instead there were no
acinar abnormalities, and only a mild suppression of endocrine cell
number, with a 60% decrease in the number of islets. The lack of an
acinar phenotype here may be due to a mosaic expression of pdx1-cre
since all of the acinar tissue appeared to have escaped deletion andwas
thus β-catenin-positive. The endocrine differences in this study are
harder to understand, but could be due to the fact that the β-catenin
conditional mutant mice had one β-catenin null mutant allele, so that
the effectiveness of β-catenin deletion in individual cells may have
been more effective.
A role for Wnt signaling in later-gestation endocrine development
has also been found. In zebraﬁsh, either frz2 or Wnt5 inhibition with
morpholinos led to failed migration of insulin-positive cells and
improper formation of islets (Kim et al., 2005). This phenotype was
non-cell autonomous, likely related to migration guidance, since frz2
was only expressed in cells adjacent to insulin-positive cells. Wnt5a
null mutant zebraﬁsh had grossly normal pancreases, but had
disrupted islet architecture, suggesting a role speciﬁcally in migration
and islet aggregation.
Lastly, there appears to be a role for Wnt signaling in promoting
post-natal pancreatic growth. Late pdx1-cre-induced β-catenin
stabilization led to a striking 4.6-fold increase in pancreatic size in
adult mice (Heiser et al., 2006) (see Fig. 10). When a similar
conditional approach was used to stabilize β-catenin in insulin-
expressing cells, only large islets and insulin hypersecretion were
seen, conﬁrming an overall growth promoting effect of β-catenin onmultiple pancreatic cell types. Along similar lines, conditional over-
expression of axin, which promotes β-catenin destruction, led to small
islets with less insulin-positive cells (Rulifson et al., 2007).
Thus, these studies of Wnt signaling reﬂect multiple important
roles for Wnts, particularly the canonical Wnt-β-catenin pathways, in
all aspects of pancreatic development. The complex and varied nature
of the different reports is reﬂective of the extreme complexity of Wnt
signaling, and further studies will likely continue to delineate the
exact mechanisms involved.
Blood vessels and endothelial-derived factors
Recently there has been increased interest in the role of
endothelial cells and possibly blood ﬂow in pancreatic development,
especially endocrine cells. Teleologically, the known dependence of
endocrine cells on an intimate relationship with capillaries for proper
function would predict a carefully orchestrated, interdependent
developmental process between endothelial cells and endocrine
cells. At E8 the dorsal aortae fuse between the notochord and the
dorsal foregut. Here, Lammert et al., used in vitro tissue interaction
studies to show that the aortic endothelial cells could induce
pancreatic bud-like structures and pdx1 expression in the adjacent
endoderm, as well as subsequent insulin expression (Lammert et al.,
2001) (see Fig. 6), and insulin-positive cell proximity to endothelium
was observed in vivo in normal development. Removal of the dorsal
aorta from Xenopus embryos led to the absence of pancreatic
endocrine development. Interestingly, transgenic ectopic over-
expression of VEGF-A under a pdx1 promoter led to more vessels
and more islets (in exchange for much less acinar tissue), and ectopic
insulin-positive cells in the stomach (Lammert et al., 2001). These
ectopic islets suggest a threshold effect of blood vessel signaling since
endothelium is normally present in the stomach, albeit at a lower level
than in the VEGF overexpression system, but islets do not normally
form in the stomach. Thus, endothelial cells appear to be a key
instructive regulator of pancreatic endocrine commitment and
differentiation. In a follow-up study, Lammert et al., showed that
mice engineered to have VEGF-A deleted speciﬁcally from pdx1-
expressing cells speciﬁcally lack islet capillaries (Lammert et al., 2003).
A more recent study by Yoshitomi and Zaret showed that endothelial
cells are necessary for PTF1a expression speciﬁcally in the dorsal
foregut, and for evagination of the dorsal foregut. Interestingly, in
contrast to the dorsal pancreas, even though the ventral foregut and
ventral pancreatic bud evagination are in proximity to the vitelline
veins, ventral pancreas formation is not dependent on endothelium
(Yoshitomi and Zaret, 2004).
Beyond the role of endothelial cells, it appears that factors
speciﬁcally carried in the bloodstream may have some key regulatory
roles in pancreatic development. N-cadherin null mutant animals
were found to developwith absence of the dorsalmesenchyme and no
dorsal pancreas (Esni et al., 2001). However, a subsequent study found
that if cardiac function was rescued in these null mutant animals (the
global mutant animals' heart fails to form properly) through speciﬁc
transgenic expression of N-cadherin only in the heart, then pancreas
formation was also rescued, presumably due to maintaining blood
ﬂow to the pancreatic anlage (Edsbagge et al., 2005). Here,
sphingosine-1-phosphate was found to be a blood-borne agent that
acts through the S1P receptor to recruit and induce proliferation of
pancreatic mesenchymal and endothelial cells. They proposed that
immature embryonic vessels are leaky, and that S1P leaks out of the
aorta from the embryonic blood to then attract dorsal mesenchyme to
grow and intervene between the notochord and the dorsal foregut
endoderm. A recent study suggested that these results could reﬂect a
role for blood ﬂow in affecting endothelial cells in their inductive
capacity (Jacquemin et al., 2006). VEGF receptor null mutant mouse
embryos lacked early pancreatic dorsal mesenchyme due to the
absence of stimuli from the dorsal aorta. This study showed that
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a later inﬂuence of dorsal aorta on the intervening dorsal pancreatic
mesenchyme exists, with dorsal aorta inducing FGF10 expression in
the dorsal pancreatic mesenchyme.
Later in development, as endocrine cells start to form, there is a
carefully orchestrated interplay between endocrine cells and endo-
thelial cells. Early E13.5 endocrine cells express angiogenic VEGF-A and
angiopoietin, and are in immediate proximity to developing capillaries
(Brissova et al., 2006). By E16.5 there is bloodﬂowing todeveloping islet
cells prior to their assembly into mature islets. Interestingly, the
developingendocrine cells donot form their ownbasementmembrane,
and thus are dependent on endothelial cells to make the basement
membrane for them (Nikolova et al., 2006). Furthermore, endocrine
cells are stimulated by basementmembrane-derived laminin, bound to
β1-integrins on the endocrine cells, to proliferate and to increase
insulin synthesis. Islet cell-derived VEGF-A appears to be necessary for
proper formation of endothelial fenestrations, and therefore for proper
glucose sensing (Brissova et al., 2006). Thus, throughout development
there is a complex and ever-changing relationship between foregut
endoderm, endocrine cells, endothelium,mesenchyme, andbloodﬂow.
Glucagon-family (and other peptide hormones) signaling
The glucagon family of peptide hormones includes the glucagon-
like peptide 1 (GLP-1) and GLP-2, and also includes glucose-
dependent insulinotrophic peptide (GIP), secretin, VIP, and others.
While the role of these peptides has generally been well-studied in
endocrine physiology, roles in pancreatic development are only
recently becoming apparent.
Glucagon
As early as 1973, cells in the early rat pancreas at the time of
evagination from the foregutwere found to haveα-granules containing
glucagon (Rall et al., 1973). Since the known metabolic functions of
glucagon are not yet relevant to the embryo's overall physiology at that
early embryonic stage, it seemed plausible that glucagon may have a
speciﬁc developmental role. Several lines of evidence suggest that
glucagon signaling is necessary for the early differentiation of insulin-
expressing cells. First, in vitro studies of cultured pancreas show that
glucagon is necessary for early formation of insulin cells (E11–E13), but
not later in the E15 pancreas (Prasadan et al., 2002). Glucagon is
speciﬁcally generated frompro-glucagon by the action of pro-hormone
convertase2 (PC2), whereas PC1/3 acts on pro-glucagon to generate
GLP-1 and other products. PC2 null mutant animals, which lack
glucagon showed a similar loss of early insulin-expressing cells, with
retention of the secondary wave of insulin-expressing cells (Vincent et
al., 2003). PC2 is also responsible for generating other peptide
hormones, but a speciﬁc role for glucagon itself was suggested when
a glucagon receptor nullmutantmousewas found to have a similar lack
of early insulin-expressing cells (Vuguin et al., 2006). These studies
together strongly implicate glucagon signaling, through the glucagon
receptor, in the initiation of early insulin-positive differentiation. In in
vitro studies, exogenousGLP-1 analogue (exendin-4)was able to rescue
this early insulin differentiation in the absence of glucagon, though the
signaling mechanism was not certain, and speciﬁc inhibition of GLP-1
signaling in the early pancreas had no effect on early insulin-positive
differentiation (Prasadan et al., 2002).
GLP-1
A role for GLP-1 in insulin-positive differentiation has been
aggressively pursued since GLP-1 is known to promote insulin
synthesis and secretion in β cells, as well as promoting β-cell growth
(Stoffers et al., 2000; Buteau et al., 1999, 2001). Also, the GLP-1
analogue exendin-4 can convert AR42J cells (Zhou et al., 1999; Yew etal., 2004) and ARIP cells (Hui et al., 2001) into insulin-expressing cells.
A developmental role for GLP-1 is suggested, but not yet clear. GLP-1
receptor null mutant mice do not have an embryonic phenotype
(Scrocchi et al., 1996). GLP-1 receptor is expressed at only low levels in
the early embryonic pancreas, but then upregulates coincident with
the secondary transition at E15 (Prasadan et al., 2002). GLP-1 exists in
at least four forms, and the receptor signaling pathways for those
different forms is not fully understood. Although mature α-cells have
PC2 and make glucagon, they do not have PC1/3 and therefore do not
make GLP-1. However, Wilson et al. found that immature glucagon-
positive cells in the embryonic pancreas do in fact have PC1/3, and
therefore presumably make GLP-1 (Wilson et al., 2002). Suzuki et al.,
showed that a lesswell-studied formof GLP-1 (GLP-1-37), which unlike
other GLP-1 forms is present in α-cells, could stimulate formation of
insulin/glucagon double-positive cells in the epithelium of the
embryonic pancreas or in ducts (Suzuki et al., 2003). As will be
discussed in the “Overview of endocrine pancreas lineage selection”
section, the early insulin/glucagon double-positive cells may represent
the ﬁrst wave of endocrine cells during early pancreas development.
Less well-studied forms of GLP-1 were strongly upregulated in
glucagon-receptor null mutant mice, and compensation by these
other forms may explain the relatively weak embryonic phenotype in
thosemice (Gellinget al., 2003; Parker et al., 2002). Further support for a
possible compensation by GLP-1 comes from a streptozotocin model of
β-cell regeneration, wherein α-cells produced more GLP-1 during β-
cell regeneration, and GLP-1 receptor inhibition blunted this β-cell
regeneration (Thyssen et al., 2006).
Besides GLP-1, the other incretin molecule is GIP, which actually
makes up 80% of the normal “incretin effect” (Gault et al., 2003)
(“incretin effect” is deﬁned as enhanced insulin secretion after an
intestine-derived glucose load). GIP has also been implicated in β-cell
development. GIP receptor, like the glucagon receptor and GLP-1
receptor, is expressed on β-cells (Huypens et al., 2000). GIP signaling
leads to altered expression of important pancreatic endocrine
transcription factors, including GATA4, Isl1, and pdx1 (Jepeal et al.,
2005), and a GIP analogue is able to enhance insulin-positive
differentiation in embryonic stem cells (Marenah et al., 2006).
However, GIP receptor null mutant mice and GLP-1 receptor/GIP
receptordoublenullmutantmice have normal pancreatic development
(Miyawaki et al., 1999; Hansotia et al., 2004), so the exact role of GIP in
pancreatic development remains unclear.
Beyond the glucagon family, other peptide hormones have been
studied for a possible direct signaling role in pancreatic development.
Mice with a double mutation for insulin I and II have large islets, but
have no developmental defects (Duvillie et al., 1997, 2002). Maternal
insulin is unlikely to be rescuing development in these insulin-
knockout animals since insulin does not readily cross the placenta
(Widness et al., 1983). The pancreatic polypeptide family of peptides
(PP, PYY, and NPY) has been studied mainly for a possible role as a
marker of progenitor cells (see “Overviewof endocrinepancreas lineage
selection” section), but no speciﬁc signaling role in development has
been found other than localization of a key PYY receptor, Y1, to non-
endocrine pancreatic cells in the vicinity of potential early endocrine
progenitor PYY-positive cells (Jackerott and Larsson, 1997).
Extracellular matrix and cell adhesion molecules
Beyond the clearly established role of mesenchyme in the
induction of exocrine and endocrine pancreatic development, the
extracellular matrix molecules in the mesenchyme, especially in the
basement membrane, play multiple important roles. The pancreatic
epithelium is contained within a continuous sheath of basement
membrane that creates the epithelial–mesenchymal interface
(Hisaoka et al., 1993). There are microscopic breaks in this sheath in
the region where early endocrine cells are forming. In other organs,
branchingmorphogenesis is tightly regulated by basementmembrane
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localized to the basement membrane at the pancreatic epithelial–
mesenchymal interface (Hisaoka et al., 1993) at early gestational times
in rat embryos. Laminin-1 has been shown to play a role early in
gestation where it is present in the mesenchyme, then becomes
focused to the epithelial–mesenchymal interface and then, through
interactions with epithelial α6-containing integrins, mediates
pancreatic duct formation (Crisera et al., 2000a). Matrigel, whose
major constituent is laminin-1, was found to induce duct formation in
isolated E11 mouse pancreatic epithelium (Gittes et al., 1996). Later, Li
et al., showed that laminin-1 mediates the pro-exocrine effects of
mesenchyme (Li et al., 2004). Laminin-1 has been shown to have a
pro-β-cell role slightly later in gestation. Speciﬁcally, laminin-1 as a
substrate enhanced β-cell differentiation in dispersed E13 pancreatic
epithelial cells, through binding to α-dystroglycan (Jiang et al., 1999,
2001). Lastly netrin-1, a diffusible laminin-like molecule that is known
to regulate neuron and axon guidance (De Breuck et al., 2003) is
present adjacent to E15–E18 pancreatic exocrine and endocrine cells,
along with the netrin receptor neogenin (Fitzgerald et al., 2006). The
other netrin receptor, DCC, may serve a function later in development
to guide neural crest migration into the pancreas to form pancreatic
ganglia (Jiang et al., 2003). Cirulli's group reported that netrin is
localized to epithelial cells at their basal surface and binds α6β4 and
α3β1 integrin during pancreatic epithelial adhesion and migration
(Yebra et al., 2003). A more general role for integrin–matrix
interactions in the developing human pancreas was shown by Cirulli
et al. wherein epithelial αvβ5 and αvβ3 integrins interacted with
ﬁbronectin, collagen-IV, and especially vitronectin to both maintain
extracellular matrix anchorage (αvβ5) and to allow epithelial
migration (αvβ3). Here, the expression pattern of these three matrix
components was suggestive of their role in the migration of endocrine
progenitor cells out of ducts to form islets. Further support for this role
of matrix guidance of migration comes from human fetal explants that
failed to form proper islets when treated with cyclic RGD inhibitors of
the αvβ3/5 integrins (Cirulli et al., 2000).
In addition to interactions with the extracellular matrix, cell–cell
adhesion also appears to be very important inpancreatic development.
Cadherins are calcium-dependent cell membrane-bound molecules
that mediate cell–cell adhesion and the sorting of different cell
populations. As described in theWnt signaling section above, cadherin
intracellular carboxyl tails interact with catenins to help form tight
junctions between epithelial cells. E-cadherin and R-cadherin are
localized to ducts, and then are down-regulated as cells move out of
the ducts to start to form islets (Dahl et al., 1996; Sjodin et al., 1995). N-
cadherin showeda different pattern thanR- or E-cadherin, localizing to
mesenchyme but not epithelium in the E9.5 pancreas. After E9.5, N-
cadherin then became localized to the endoderm, and by E12.5 was
only in the islets (Esni et al., 2001). As discussed earlier, the absence of
N-cadherin in the pancreas has no effect on pancreatic development.
However, forced dominant-negative E-cadherin expression in β-cells,
which inhibits both E-cadherin and N-cadherin signaling, led to a
speciﬁc loss of embryonic β-cell aggregation, with islets consisting
only of α-cells (Dahl et al., 1996). Thus, collectively the cadherins
appear to play important roles in migration and differentiation of
pancreatic endocrine progenitor cells.
Another cell adhesion molecule, N-CAM, which is expressed in
mature α- and PP-cells (Cirulli et al., 1994), is localized to epithelium
and mesenchyme early in pancreatic development and, similar to N-
cadherin, it becomes restricted to endocrine cells by E11.5 (Esni et al.,
1999). N-CAM null mutant embryos had improperly aggregated
endocrine cells within the islet.
A unique role was found for another matrix molecule, Ep-CAM in
human fetal pancreas, where interestingly Ep-CAM was upregulated
speciﬁcally in endocrine cells as they began to migrate out of the early
embryonic ducts, but then was downregulated as the islet cells
matured (Cirulli et al., 1998). Further support for a role for Ep-CAM inmaintaining a ductal endocrine progenitor was found when inhibition
of Ep-CAM in vitrowith antibodies induced endocrine cell maturation
and hormone production.
Other extracellular molecules
In addition to the now fairly extensive list of signaling molecules
that have been studied in-depth in the developing pancreas,
numerous other molecular pathways with potentially important
inﬂuences on pancreatic development have been studied, though in
less detail. The Scharfmann laboratory has initiated many of these
studies. For example, vasoactive intestinal peptide (VIP) and pituitary
adenylate cyclase-activating polypeptide (PACAP) are both paracrine-
acting proteins that can stimulate cAMP production and growth in E13
embryonic pancreatic epithelium, with enhanced numbers of amy-
lase-positive and insulin-positive cells. The common receptor for
these two peptides, VPAC2, colocalizes with pdx1 in E12 to E16
pancreatic rat epithelium, and turns off when the cells become insulin
or glucagon-positive, suggesting a key role for VPAC2 signaling in
controlling growth and lineage selection of uncommitted pancreatic
progenitor cells (Rachdi et al., 2003). In zebraﬁsh the same group
found that calsenilin, a neuronal presenilin regulator, identiﬁed
through an endocrine pancreas expression screen, was present in all
endocrine cells. A role for calsenilin in promoting endocrine
differentiation was suggested by the fact that calsenilin-inhibition
with morpholino antisense led to markedly decreased numbers of
endocrine cells, with failure of residual endocrine cells to aggregrate
into islets (Stetsyuk et al., 2007).
Recently the Scharfmann laboratory found the surprising result
that glucose was speciﬁcally necessary for endocrine, but not exocrine
development in in vitro cultured pancreas. In the absence of glucose
(except possibly for some glucose in the added serum), exocrine
pancreas developed normally, but endocrine progenitors were unable
to progress past the ngn3-positive stage (Guillemain et al., 2007).
An interesting role for glucocorticoid receptor signaling in
regulating β-cell mass has recently been shown by the Breant
laboratory. Late-gestational malnutrition in pregnant rats led to
decreased fetal β-cell mass due to a decreased numbers of islets
(Garofano et al., 1997), which seemed to translate to poor
proliferation and greater senescence of β-cells in adult mice
(Garofano et al., 1998, 1999, 2000). These studies suggested that
type II diabetes may stem from in utero and perinatal insults with
enhanced glucocorticoid levels, which would then decrease β-cell
mass and islet numbers (Blondeau et al., 2001). Interestingly, this in
utero effect of glucocorticoids on β-cell mass was originally
suggested by early studies of protein levels in E14 rat pancreas in
which dexamethasone treatment enhanced amylase levels and
suppressed insulin levels (Van Nest et al., 1983), and was then
later supported by the observation that dexamethasone had a similar
pro-exocrine and anti-insulin effect on AR42J cells (Shen et al.,
2003). More recently, the Breant laboratory conﬁrmed that
dexamethasone could enhance acinar development and suppress
β-cell development (Gesina et al., 2004). The glucocorticoid receptor
was implicated here speciﬁcally in β-cell development, since pdx1-
cre-mediated β-cell-speciﬁc ablation of the glucocorticoid receptor
speciﬁcally caused a doubling of the number of β-cells, with no
effect on other cell types. However, the effect of the glucocorticoid
receptor was not due to a role in mature β-cell function since
glucocorticoid receptor deletion under RIP-cre control, which would
delete the glucocorticoid receptor later on in developing insulin-
positive cells, resulted in no loss of β-cells (Gesina et al., 2004).
An observation in the early pancreatic development literature that
is important to remember for developmental studies is a direct effect
of BrdU on pancreatic differentiation. BrdU at 20 µM inhibited acinar
differentiation in E14 rat pancreas, and the pancreas appeared to
develop with more ducts (Githens et al., 1976). It was also shown in
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exchange for elevated levels of possible ductal proteins.
Another potential signaling pathway affecting pancreatic develop-
ment is through the stem cell factor receptor c-kit, (Li et al., 2007).
Signaling through this receptor may lead to endocrine differentiation
by cells lining the early pancreatic ducts, and c-kit is present in
human fetal duct cells, and then later in endocrine cells. C-kit
stimulation in cultured human fetal pancreas led to enhanced insulin
expression and proliferation of insulin-positive cells. Furthermore,




Pancreatic development over the last 15 years has been dominated
by studies of transcription factors and transcription factor hierarchies
during development. A central and heavily studied transcription factor
in pancreatic development is pancreatic duodenal homeobox 1 (pdx1).
Pdx1 was originally identiﬁed based on its ability to bind the insulin
and somatostatin genes, and has also been called stf1, idx1, ipf1, and
the Xenopus ortholog, x1Hbox8 (Ohlsson et al., 1991; Leonard et al.,
1993; Ohlsson et al., 1993; Miller et al., 1994; Peshavaria et al., 1994).
Pdx1 is only expressed in the foregut and its derivates, and is ﬁrst
expressed at E8.5 (10 somites) in the pre-pancreatic region of the
mouse foregut, and then expands to be expressed in the distal stomach,
common bile duct, and duodenum by E10 to E11.5 (Ofﬁeld et al., 1996;
Guz et al.,1995; Jonsson et al.,1995;Wessels and Cohen,1967). This 10-
somite onset of pdx1 expression correlates with the earliest point at
which ex vivo foregut can form pancreas, and suggests that pdx1 is a
key component of pancreatic speciﬁcation. In the early pancreas, pdx1
is expressed throughout the epithelium, but then is suppressed in cellsFig. 11. Null mutant mice for pdx1 (also called ipf1 or idx1) were born with agenesis of the
(with permission (Jonsson et al., 1994). Further investigations showed that these mice h
pancreas (dp) (C and D). Similarly, insulin cells are present (arrow), but in greatly diminishas they commit to the endocrine lineage (as cells move out of the
epithelium and express glucagon) (Jensen et al., 2000b), or commit to
ducts (Jonsson et al.,1995; Gu et al., 2002) (see Summary and overview
of endocrine pancreas lineage section for more details). As endocrine
cells begin to differentiate toward the insulin-positive β-cell lineage,
pdx1 reappears, and is known to be necessary for proper glucose-
responsive regulation of insulin synthesis in β-cells (MacFarlane et al.,
1994; Marshak et al., 1996). Low pdx1 expression persists in other
endocrine cell types, acinar cells and ductal cells (Guz et al., 1995; Wu
et al., 1997), though without a clear developmental role.
In 1994 the Edlund laboratory in Umea, Sweden published a
landmark paper in which pdx1 (then called ipf1) null mutant mice
were created, and found to have pancreatic agenesis (Jonsson et al.,
1994). In a follow-up study, an early pancreatic dorsal bud was
detected in these mice, although no ventral bud was ever seen. This
dorsal bud persisted, forming a few insulin and glucagon-expressing
cells, but without expansion of those cells (Ahlgren et al., 1996) (see
Fig. 11). A similar exon-2 deleted pdx1 null mutant mouse was
described two years later in which a similar early abortive dorsal bud
formed, with only glucagon-expressing cells, no insulin-expressing
cells, and metaplasia of the duodenal mucosa into a bile duct
phenotype associated with duodenal obstruction (Ofﬁeld et al.,
1996). Clearly, pdx1 is not necessary for early budding of the dorsal
pancreas, nor for early endocrine cells to form, but is necessary for
later steps in pancreatic development. Following these null mutant
mouse studies, pdx1 mutations in humans were found to be
associated with pancreatic agenesis in homozygous null mutants
(Stoffers et al., 1997b), and with insulin insufﬁciency in heterozygous
mutants (Dutta et al., 1998; Stoffers et al., 1997a). Zebraﬁsh with pdx1
null mutations are also apancreatic (Yee et al., 2001).
Because of its obviously central role in pancreatic and β-cell
development and function, an unprecedented number of mutant
mouse strains designed to study pdx1 regulation have been generated.pancreas (p), with occasional duodenal (d) obstruction (A, B) and a dilated stomach (s)
ad an attenuated dorsal pancreatic rudiment (dpr) compared with wild-type dorsal
ed numbers in null mutant animals (E and F) (with permission, Ahlgren et al., 1996).
21G.K. Gittes / Developmental Biology 326 (2009) 4–35Key studies from the MacDonald laboratory used a tetracycline-
regulatable transgenic knock-in system to study the role of pdx1 after
initial budding of the dorsal pancreas. With this delayed inhibition of
pdx1 expression until after budding, there was severe blunting of
pancreatic development, with only small ductal structures present,
and complete absence of acini or β-cells. These results conﬁrmed an
ongoing important and necessary role for pdx1 in early acinar and
endocrine development (Holland et al., 2002) subsequent to the initial
formation of a pancreatic bud. Beyond this initial acinar development,
subsequent maturation and growth of acini also seems to be pdx1-
dependent. Later inhibition of pdx1 expression (E13.5 to E14) resulted
in reduced numbers of acini, and the acini that were present were
immature (Hale et al., 2005).
To further delineate the role of pdx1 in pancreatic development,
the Wright laboratory has generated numerous important pdx1
mutant mouse strains. By deleting key 5′ regulatory elements, a
hypomorphic pdx1 allele was created that led to delayed and
diminished pdx1 expression. Using this hypomorphic allele (Δ) in a
pdx1 null mutant background enabled the study of how different
levels of pdx1 may affect pancreas development.(Fujitani et al., 2006).
Mice with one hypomorphic allele and one null allele (Δ/−) were
found to phenocopy the homozygous null mutant mice. With the next
higher “dose” of pdx1 expression, Δ/Δ mice developed a pancreas
with markedly diminished β-cells and no islets. Here, the distal half of
the developing dorsal pancreas appeared atretic, with no acini,
whereas the proximal half was clearly demarcated and had normal-
appearing acini. Surprisingly, no ventral bud was seen due to a lack of
ventral foregut PTF1a (see “PTF1a” section). Lastly, mice with one
normal pdx1 allele and one hypomorphic pdx1 allele (Δ/+) had
replacement of β-cells with α-cells and PP cells, with α-cells
throughout the islet instead of only at the periphery. These mice
were also glucose intolerant, suggesting deﬁcient β-cell function.
Thus, this study demonstrates a key role for proper pdx1 gene
regulation and dosing in multiple aspects of pancreatic endocrine and
exocrine development, including early pancreatic commitment,
exocrine/acinar differentiation, endocrine lineage selection, and β-
cell function. The ﬁnding of glucose intolerance in the Δ/+ mice was
not surprising given the wealth of data supporting that pdx1
heterozygous mutant β-cells are dysfunctional (Johnson et al., 2003;
Brissova et al., 2002; Dutta et al., 1998; Boyer et al., 2006), and are
unable to undergo compensatory hypertrophy (Kulkarni et al., 2004).
The ﬁnding that Δ/+ β-cells were replaced by α-cells (and PP-cells) is
consistent with studies in which pdx1 inhibition in β-cells (using
either tetracycline-induced pdx1 inhibition (Lottmann et al., 2001;
Thomas et al., 2001a; Holland et al., 2002) or insulin promoter-driven
cre excision of pdx1 (Ahlgren et al., 1998; Gannon et al., 2008) led to
β-cell depletion and a concomitant rise in the number of α-cells. This
phenotypic change is not due to conversion of β-cells to α-cells, but
rather seems to be due to the loss of normal β-cell inhibition of α-cell
development (Gannon et al., 2008). Earlier deletion of β-cell pdx1
seems to lead to greaterα-cell growth. Although pdx1 is co-expressed
in early glucagon cells (Jensen et al., 2000b; Chiang andMelton, 2003),
pdx1 in those cells may actually be acting to down-regulate glucagon
expression and prevent α-cell differentiation, perhaps through
competitively binding pax6 sites on the glucagon gene (Chakrabarti
et al., 2002; Ritz-Laser et al., 2003; Flock et al., 2005).
Beyond the major pdx15′ prime regulatorymutations described in
detail above (Fujitani et al., 2006), the Wright laboratory has delved
deeply into the detailed developmental roles for several of the pdx1
regulatory elements, which overall are designated areas I through IV
(in order fromproximal to distal to the transcriptional start site). Areas
I through III are highly conserved (Gerrish et al., 2000; Marshak et al.,
2000) and were deleted in the hypomorphic Δ allele described above.
This I–III region confers expression of pdx1 in the early pancreas and
duodenum (Gannon et al., 2001; Stoffers et al., 1999; Wiebe et al.,
2007). Areas I and II appear to confer β-cell speciﬁcity (Wiebe et al.,2007; Samaras et al., 2002; Van Velkinburgh et al., 2005), perhaps in
cooperation with area IV (Gerrish et al., 2004). Area IV is involved in
suppression of pdx1 in non-endocrine β-cells, in expression of pdx1 in
the gut, and in development of the GIP-positive and gastrin-positive
cells in the gut (Boyer et al., 2006). The overexpression of pdx1 under
the PTF1a promoter resulted in no developmental changes (Miyatsuka
et al., 2006).
Pdx1–pbx-1 interactions
Beyond the role of pdx1 as a monomer, its function also appears to
be heavily dependent on interactions with other molecules present
inside the cells. Pdx1 has a critical protein–protein interaction with
pbx-1, a member of the TALE (three-amino-loop extension) class of
homeodomain transcription factors (Dutta et al., 2001). Pdx1 and
pbx1 have been found to interact with each other, and with other
potential third partners to form a transcriptional regulatory complex
that may play a role in pancreatic differentiation (Peers et al., 1995;
Swift et al., 1998). Pdx1: pbx-1 heterodimers have a twenty-fold
greater afﬁnity for the insulin gene (Peers et al., 1995), but surprisingly
a pdx1 mutant that cannot interact with pbx-1 is still able to rescue
the diabetic phenotype of pdx1 heterozygous null mutant mice (Dutta
et al., 2001). However, although the embryos of these pdx1 interaction
mutants could specify pancreatic cells, and all cells types were
present, cell types appear unable to amplify after initial commitment.
This pbx-1 requirement for proper pdx1 function is also suggested by
chick electroporation studies wherein ectopic pdx1 expression in the
foregut (without concomitant pbx-1 expression) could induce
pancreas-like evaginations to occur, with suppression of intestinal
patterning factors, but with no further pancreatic differentiation or
growth (Grapin-Botton et al., 2001).
Further evidence for a role for pbx-1, perhaps partly independent
of its pdx-1 interactions, came from studies of a pbx-1 null mutant
mouse (Kim et al., 2002). Pbx-1 was expressed in both epithelium and
mesenchyme (pdx1 is not ever expressed in the mesenchyme) in the
early embryo, and then became localized to ducts and islet cells later
in development and postnatally. Pbx-1 null mutant mice lacked
endocrine and exocrine differentiation. The lack of endocrine cells was
due to the absence of pbx-1 in the epithelium, presumably in a cell-
autonomous fashion, whereas the lack of exocrine cells was likely due
to loss of a pbx-1-induced pro-exocrine mesenchymal factor.
PTF1a
PTF1a, or p48, was originally described as part of a large
heterotrimeric transcriptional regulator complex called pancreas-
speciﬁc transcription factor 1 (PTF1), which regulates acinar enzyme
gene expression (Cockell et al., 1989; Petrucco et al., 1990). PTF1a or
p48 is a basic helix–loop–helix protein that is the only cell-speciﬁc
component of the PTF1 heterotrimer (Krapp et al., 1996). PTF1a
appears to play an important role in early speciﬁcation of pancreatic
progenitor cells. PTF1a is ﬁrst expressed slightly later than pdx1, at
E9.5, speciﬁcally in cells of the foregut endoderm destined to give rise
to dorsal and ventral pancreas (Burlison et al., 2008; Krapp et al.,
1998). This early PTF1a expression in the dorsal pancreas is likely due
to the inﬂuence of the nearby dorsal aortae (see “Blood vessels and
endothelial-derived factors” section) (Yoshitomi and Zaret, 2004).
Unlike pdx1, PTF1a is not expressed in other parts of the foregut. PTF1a
expression continues mainly in epithelial and acinar cells, but
expression is decreased in endocrine cells. Low level expression of
PTF1a can be present in early endocrine progenitor cells (Kawaguchi et
al., 2002; Chiang and Melton, 2003; Lin et al., 2004b; Zecchin et al.,
2004; Zhou et al., 2007). By lineage tracing analysis, essentially all
acinar cells, 95% of ductal cells, 75% of α-cells, and 100% of non-α
endocrine cells are derived from PTF1a-positive progenitor cells.
PTF1a and pdx1 are co-expressed in pancreatic progenitor cells
from E9.5 to E12.5. Pdx1 is expressed in a much broader domain than
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on PTF1a expression. However, Area III of the pdx1 promoter, which
contributes to early embryonic pdx1 expression, can be bound and
activated by PTF1a (Wiebe et al., 2007). Also, PTF1a expression is not
dependent on pdx1 expression (Kawaguchi et al., 2002; Lin et al.,
2004a). There is evidence that progenitor cells co-expressing pdx1
and PTF1a are instructed toward a pancreatic fate. Loss of hes1
expression (hes1 is a downstream target of notch, see “Notch
signaling” section) in pdx1-expressing stomach, duodenum, and bile
duct progenitors diverted those cells to a pancreatic fate (Fukuda et al.,
2006; Sumazaki et al., 2004). Similarly, early transgenic expression of
PTF1a in liver, stomach, and duodenum can divert those cells into
forming pancreas (Jarikji et al., 2007; Afelik et al., 2006). When the
pdx1/PTF1a co-expressing ﬁeld in the foregut is expanded in Xenopus,
the result is a “giant” pancreas, suggesting that more pancreatic
progenitor cells were created as a result of the enhanced number of
pdx1/PTF1a co-expressing cells (Afelik et al., 2006) (see Fig. 12). A
direct correlation between pancreatic size and the number of initial
progenitor cells has been clearly documented (Stanger et al., 2007).
An important global role for PTF1a in pancreas speciﬁcation is
conﬁrmed by mouse null mutant and zebraﬁsh knockdown studies.
Like pdx1 null mutants, PTF1a null mutant mice develop with only an
aborted dorsal pancreatic bud, and a minuscule ventral bud, which
actually emanates from the bile duct (Krapp et al., 1998; Kawaguchi et
al., 2002) (see Fig. 12). In PTF1a knockdown zebraﬁsh and Xenopus
embryos, the exocrine pancreas is absent (Afelik et al., 2006; Lin et al.,
2004b). While the role of PTF1a in exocrine and acinar development is
clear, a role in endocrine development is not. In PTF1a null mutant
mice, acini and ducts do not form, but endocrine cells do develop and
migrate out through the mesenchyme to populate the spleen (Krapp
et al., 1998; Lin et al., 2004b). Similarly, humans with a PTF1a non-
functioning mutation are born without any pancreas, and have
neonatal diabetes (Sellick et al., 2004).Fig. 12. PTF1a is critical for exocrine development, and marks the pancreatic lineage. PTF1a
wild-type littermates in (A), (amylase in brown) (p, pancreas; m, mesenchyme; st, stomach). I
the insert showing clusters of insulin-positive cells (C). Insulin-positive cells are also seen al
the PTF1a/p48 ﬁeld was expanded into the entire pdx1 domain in Xenopus embryos, a massiv
animals (E) comparedwith non-transgenics (D) (with permission, Afelik et al., 2006). Kawagu
toward the pancreatic phenotype. (F) lineage tagging of PTF1a promoter-positive cells in a P
formation of the pancreas, and histologic analysis of the duodenum shows that PTF1a linea
absence of PTF1a protein (G) (with permission, Kawaguchi et al., 2002).In addition to these known roles, PTF1a has a highly orchestrated
and complex set of interactions with notch downstream intercellular
mediators (RBP-J's) to regulate target patterning genes and acinar-
speciﬁc genes (see “Notch signaling” section for details).
Neurogenin 3 (ngn3) and its targets
As described in the “Notch signaling” section earlier, ngn3 is a basic
helix–loop–helix transcription factor whose expression is repressed
by notch-mediated intracellular signaling (Apelqvist et al., 1999;
Jensen et al., 2000c; Lee et al., 2001). Ngn3 has been a key target for
study as it currently sits atop the pancreatic endocrine lineage
transcription factor hierarchy. In mouse embryos ngn3 is ﬁrst
expressed in the early pancreatic epithelium at E9 (Gradwohl et al.,
2000; Jensen et al., 2000b; Schwitzgebel et al., 2000), and then ngn3
expression escalates, it then peaks at around E15.5, but decreases
substantially by E17.5 (Gradwohl et al., 2000; Schwitzgebel et al.,
2000; Jensen et al., 2000b; Gu et al., 2002). Ngn3-positive cells are
good candidates for endocrine progenitor cells. Ngn3-positive cells are
proliferative and give rise to post-mitotic cells expressing the islet
transcription factors neuroD, nkx6.1 and pax6 (Jensen et al., 2000a).
Shortly after neuroD and pax6 are expressed, ngn3 is shut off,
apparently due in part to auto-repression (Smith et al., 2004; Gu et al.,
2002). Most importantly, favoring the progenitor cell status of ngn3-
positive cells, all pancreatic endocrine cells derive from ngn3-positive
cells (Gu et al., 2002).
Ngn3 appears to be a key driver of endocrine differentiation. In an
effort to induce non-pancreatic tissues to become pancreatic islets,
ngn3 has been expressed ectopically in multiple systems. In general,
forced expression of ngn3 induces cells to commit to the endocrine
lineage prematurely and exit from the cell cycle. When ngn3 is
expressed at high levels and at an inappropriately early time in the
developing mouse pancreas, the result is the that the entire pancreas(also called p48) null mutant mice develop with no exocrine tissue (B) compared with
n these animals, insulin-positive islets are interestingly localized to the spleen (sp), with
ong the old pancreatic mesentery (m) (with permission, Krapp et al., 1998). (D, E) When
e enlargement of the pancreas was seen, identiﬁed as the dark blue region in transgenic
chi et al. showed that PTF1a diverts foregut cells away from the duodenal phenotype and
TF1a null mutant mouse shows an attenuated pancreatic duct (arrow) without proper
ge cells are diverted to becoming duodenal mucosal villus (v) and crypt (c) cells in the
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(Apelqvist et al., 1999; Schwitzgebel et al., 2000; Johansson et al.,
2007). When chick embryonic endoderm was electroporated with an
ngn3 expression vector, the intestine was induced to express glucagon
and somatostatin, but not insulin. Overexpression of ngn3 in human
(Heremans et al., 2002) or mouse (Gasa et al., 2004; Mellitzer et al.,
2006) pancreatic duct cells could induce an endocrine program.
Ngn3 appears to have the ability to initiate the full pancreatic
endocrine program if expressed in the appropriate cells at the
appropriate time. Johansson et al., using an elegant transgenic “add-
back” system of ngn3 expression at speciﬁc times in an ngn3 null
mutant background, showed that forced ngn3 expression later, at E11
to E12 was able to induce many pancreatic polypeptide- and insulin-
expressing cells instead of the glucagon-only differentiation seenwith
earlier overexpression of ngn3 (Johansson et al., 2007). Interestingly, a
few ngn3-positive cells have been found in mature islets (Gu et al.,
2002), and ngn3 reporter mouse strains have been used to purify and
study potential embryonic endocrine progenitor cells (Mellitzer et al.,
2004; White et al., 2008). A recent landmark paper showed that ngn3
reporter mice could be used to sort cells from an E13.5 pancreas, or
from a duct-ligated adult pancreas. Amazingly, both types of cells
(adult or embryonic), when grafted into an explanted ngn3 null
mutant foregut in vitro (which normally will not form any pancreatic
endocrine cells), were able to form mature islets (Xu et al., 2008) (see
Fig. 13). This study represents strong evidence of ngn3 as a marker of
embryonic and adult-derived pancreatic endocrine progenitors.
NeuroD
Potential downstream mechanisms by which ngn3 may activate the
endocrine program are of obvious interest. Ngn3 has neuroD as an
immediate downstream target (Jensen et al., 2000b; Gradwohl et al.,
2000; Jensen et al., 2000a; Gradwohl et al., 2000; Huang et al., 2000;
Gasa et al., 2008; Gu et al., 2002) through binding and activating E-boxes
of the neuroD regulatory sequence as an ngn3-E47 heterodimer (Huang
et al., 2000). The close relationship between ngn3 and neuroD
expression is highlighted by the fact that neuroD overexpression, either
transgenically in mice, or in ductal cell lines, induces a similar
phenotypic change to that seenwithngn3overexpression (Schwitzgebel
et al., 2000; Heremans et al., 2002; Gasa et al., 2008). NeuroD expression
is dependent on ngn3 since ngn3 null mutant mice lack neuroD
(Gradwohl et al., 2000). The onset of neuroD expression in endocrine
cells of the embryonic pancreas represents a very important transition
from proliferative ngn3-positive cells to post-mitotic cells (Jensen et al.,
2000a; Gu et al., 2002). Unlike ngn3 null mutantmice, however, neuroD
nullmutantmice are still able to formall pancreatic endocrine cell types,
but the number of cells is drastically reduced due to late-gestation
apoptosis, dependingon the backgroundmouse strain (Naya et al.,1997;
Huang et al., 2002). A role for neuroD in suppressing non-β-cell lineages
has been suggested by the fact that the addition of a neuroD nullFig.13.Ngn3 can be used as amarker of endocrine progenitor cells in the embryonic pancreas
that by purifying these ngn3-positive cells from E13.5 embryonic pancreas, and then injectin
insulin cells are seen in ngn3 null mutant explants alone (B), and wild-type explants had robu
the pancreatic duct ligation model also led to the formation of clusters of strongly insulin-pmutation to Nkx2.2 null mutant mice (lacking β-, α- and PP-cells, see
later section) will rescue α and PP-cells (Chao et al., 2007).
Other potentially important direct targets of ngn3 include Insulin-
Associated 1 (IA1), a zinc ﬁnger protein that is activated by either ngn3
(Mellitzer et al., 2006) or by neuroD (Breslin et al., 2003). IA1 appears
to be important in executing the endocrine differentiation process,
since it is absent in ngn3 null mutant mice, and is normally expressed
in the early pancreatic buds (Gierl et al., 2006) and in pancreatic AR42J
cells that are becoming insulin-positive (Zhu et al., 2002). IA1 is still
expressed in the pancreas of neuroD null mutant mice, perhaps
participating in the small amount of endocrine differentiation that is
known to occur in the pancreas of those mice (Mellitzer et al., 2006;
Naya et al., 1997; Huang et al., 2002). Other ngn3 targets include
Iroquois-type Homeobox proteins (Irx 1 and 2), which are expressed
in early pancreatic endoderm and in α-cells (Petri et al., 2006), and
neuroD2, which is present in embryonic pancreas and in α-cell lines
(Gasa et al., 2008). Ngn3 also directly regulates expression of pax and
Nkx genes, which are discussed later.
Regulation of ngn3 is obviously of high importance, and positive
regulation by the HNF/Forkhead family of transcription factors
appears to play an important role in this regulation (see “HNF
cascade” section).
Pax6
Pax6 is a member of the pax family of transcription factors
containing a paired box DNA binding domain. Pax6 also contains a
second DNA binding domain, the homeodomain, and was found to be
expressed throughout the early embryonic pancreas (E9.0), and in
pancreatic endocrine cells (Turque et al., 1994). The onset of pax6
expression in the early pancreatic epithelium occurs within an
endocrine committed population of epithelial cells that also expresses
neuroD and isl1 (Jensen et al., 2000a). NeuroD, in cooperation with
E47, can bind and activate the pax6 gene (Marsich et al., 2003). These
early pax6-positive cells then begin hormone expression. Pax6
expression is retained in cells committing to the endocrine lineage,
either glucagon-positive, starting at E9.5, or insulin-positive, starting
at E12.5 (Sander et al., 1997; St-Onge et al., 1997; Heller et al., 2004).
Consistent with this hormone expression in pax6-positive cells, pax6
binding sites have been found in the A site of the G3 promoter region
of the preproglucagon gene, and similar sites are present on the
insulin and somatostatin genes (Sander et al., 1997). Consistent with
pax6-positive cells giving rise to glucagon-positive cells, at E9.5 many
epithelial cells are pax6-positive, and all of the glucagon-positive cells
at that time are included in the pool of pax6-positive cells (Jensen et
al., 2000a; Sander et al., 1997; Heller et al., 2004). Some of the early
pax6-positive cells may give rise to duct cells, as shown by a lineage
tagging study using 3.3 kb of the pax6 promoter to label cell lineages
(Zhang et al., 2003)., and in the pancreatic duct ligationmodel of pancreatitis in adult mice. Xu et al., showed
g the cells into an ngn3 null mutant foregut in vitro, insulin cells could develop (C). No
st insulin-positive differentiation (A). Similarly, sorting of adult ngn3-positive cells from
ositive cells in the ngn3 mutant explants (D) (with permission, Xu et al., 2008).
Fig. 14. Pax4 and Arx have competing roles in the determination ﬁrst of ngn3-positive
cells' commitment to either the α/PP-cell lineage or the β/δ-cell lineage. Subsequently,
once some cells are committed to the β/δ-cell lineage, persistent pax4 seems to select
for the β-cell lineage, whereas suppression of pax4 selects for the δ-cell lineage.
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expression since pax6 null mutant mice, or mice with a dysfunctional
small eye mutation of the pax6 gene, are both still able to form
endocrine cells, though at a reduced rate (St-Onge et al., 1997; Sander
et al., 1997). In these pax6mutants early (“ﬁrst wave”) insulin-positive
cells are scarce at E12.5. This absence of early insulin-positive cell
development could be due directly to the absence of pax6, or instead
due to the absence of glucagon which, as discussed earlier leads to
failure of early insulin-positive cell differentiation (Prasadan et al.,
2002; Vuguin et al., 2006). In addition to the paucity of endocrine cells
forming in pax6 mutants, there is also a failure to amplify the
endocrine cell population during the secondary transition, with an
resulting 75–100% reduction in α-cells (St-Onge et al., 1997; Sander
et al., 1997), and a 65% reduction in β-cells (Sander et al., 1997).
Heller et al. found that the more sensitive staining technique of
immunoperoxidase, rather than immunoﬂuorescence, allowed
detection of hormones in more cells of the E19 pancreas of pax6
null mutant mice, suggesting that pax6 may play a role in hormone
expression levels, rather than hormone gene activation (Heller et al.,
2004). In addition, this group later showed a population of
endocrine-like cells in the pax6 mutant pancreas at E19 that were
negative for insulin, glucagon, somatostatin, and PP. These cells were
ghrelin-positive ɛ-cells, and were ﬁve-fold more prevalent in these
pax 6 mutant mice, suggesting that pax6 normally prevents the
expression of ghrelin in pancreatic endocrine cells (Heller et al.,
2005).
A role for pax6 in islet cell and possibly duct cell growth is further
supported by mice in which transgenic expression of pax6 under the
pdx1 promoter induced ductal and islet hyperplasia (Yamaoka et al.,
2000). Speciﬁc transgenic expression of pax6 in β-cells under the
insulin promoter, however, caused β-cell apoptosis and diabetes,
suggesting that pax6 promotes proliferation only in pancreatic
progenitors.
Pax4 and Arx
A second pax family member, pax4 shows similar sequence
homology to pax6, including the presence of a homeodomain (Dahl
et al., 1997). In the early embryo, at E9.5, pax4 is expressed almost
exclusively in the pancreatic ﬁeld of the foregut (Sosa-Pineda et al.,
1997; Brink et al., 2001). The pax4-positive cell population then
expands rapidly, peaking at E13–E15 (Wang et al., 2004), coinciding
with the burst of new insulin-positive cells appearing in the secondary
transition. Here, insulin-positive cells likely arise from pax4-positive
cells since a fraction of the pax4-positive cells are insulin positive. As
the endocrine cells mature, pax4 expression, which is predominantly
in the developing β-cells, disappears (Smith et al., 1999). Thus, pax4
represents an endocrine progenitor marker that is fairly speciﬁc to the
pancreas. Lineage-tagging studies show that although pax4-positive
cells are mostly insulin cells, pax4-positive cells actually give rise
equally to the four main endocrine lineages (Greenwood et al., 2007),
suggesting that the reason that most pax4-positive cells are insulin-
positive is that they are more proliferative after expressing insulin.
Activation of pax4 in endocrine progenitor cells may be mediated by
ngn3 and HNF1α (see “HNF cascade” section) since these factors bind
the pax4 regulatory region and are necessary for pax4 expression in
cell lines (Smith et al., 2003).
A key role for pax4 in β-cell development was demonstrated by a
pax4 null mutant mouse in which there was failure to develop β-cells
and δ-cells. These mice did have early embryonic insulin-positive
cells, so pax4 seems speciﬁcally necessary only for formation of
mature β-cells (Sosa-Pineda et al., 1997; Wang et al., 2004). In the
absence of β-cells and δ-cells, the number of glucagon-positive cells
was noted to be greatly increased, as if replacing the β-cells. These
glucagon-positive cells were actually found to co-express glucagon
and ghrelin (Heller et al., 2005; Wang et al., 2008). Mechanistically,this expansion of a glucagon/ghrelin double-positive cell populations
likely reﬂects that pax4 can act as a transcriptional repressor, being
especially effective at repressing ghrelin expression and pax6-
mediated glucagon expression (Wang et al., 2008; Smith et al.,
1999; Ritz-Laser et al., 2002).
Pax4 also directly inhibits expression of Arx, a homeobox-
containing gene that enhances glucagon-positive cell differentiation
(Collombat et al., 2003, 2005). Although pax4 null mutant mice lack
somatostatin-positive δ-cells, a positive role for pax4 in δ-cell
development remains unclear since double null mutant mice for Arx
and Pax4 show large numbers of δ-cells, suggesting that persistent
pax4 expression after the initial β/δ versus α/PP switch favors β-cells,
but then the absence of pax4 secondarily leads to δ-cell formation
(Collombat et al., 2005) (see Fig. 14).
Arx is downstream of ngn3 since it is absent from ngn3 null
mutant mice. Arx null mutant mice have noα-cells, mainly due to loss
of secondary transition glucagon-positive cells (Collombat et al.,
2003), and the α-cell precursors seem to be shunted toward the β-cell
and δ-cell lineages due to unopposed pax4 expression (Collombat et
al., 2003, 2005). Conversely, overexpression of Arx in pdx1-positive
progenitor cells was able to divert most β-cell and δ-cell precursors
towardα-cells and PP lineages (Collombat et al., 2007), with no change
in the total number of endocrine cells, again supporting opposing roles
for pax4 and Arx in α/PP cells versus β/δ cells. Here it should be noted
that Arx does not directly downregulate pax4 since Arx overexpressing
cells had persistent pax4 expression. An additional role for Arx, in
endocrine-versus-exocrine lineage selection, was suggested by the fact
that the pdx1-Arx-transgenic mice had a loss of exocrine cells.
Lastly, although ngn3 expression is thought to be an irreversible
commitment to the endocrine lineage, overexpression of a
constitutively-active notch mediator in the pax4-positive subset of
ngn3-lineage cells led to a surprising metaplasia of the cells into
ducts (Greenwood et al., 2007). Thus, these pax4-positive cells may
still represent an important multi-potent progenitor cell.
Nkx2.2
Nkx2.2 is a member of the NK family of homeodomain proteins
that also contains engrailed-homologous repressor domains (Muhr
et al., 2001). Nkx2.2 was identiﬁed as having a role in neuronal
differentiation, and then was noted to also be expressed in α- and β-
cells (Rudnick et al., 1994). Nkx2.2 is expressed in the early embryonic
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of the epithelial cells are Nkx2.2-positive, and all of those Nkx2.2-
positive cells co-express pdx1 (Chiang and Melton, 2003). As
pancreatic development progresses, Nkx2.2 expression becomes
focused to ngn3-positive cells, and persists in most endocrine cells,
except not at all in the δ-cells (Sussel et al., 1998). Interestingly,
expression of Nkx2.2 in these three different phases (i.e. early bud,
ngn3-positive endocrine progenitors, andmature/maturing endocrine
cells) appears to be under the control of three different ﬁrst exons,
each exon having different regulatory elements (Watada et al., 2003).
The “A” ﬁrst exon is expressed only in hormone-positive or hormone-
negative/ngn3-positive cells at E10.5, and then accounts for most of
the Nkx2.2-expression in the E15 pancreas. In mature islets, the A
exonwas only expressed in β-cells. This A exon is regulated by HNF3β/
FoxA2 (see “HNF cascade” section) bound to either the ngn3 gene
(presumably for the embryonic expression) or neuroD (presumably
for β-cells and other hormone-positive cells). The “B” ﬁrst exon was
expressed only in ngn3-positive cells, and then turned off when the
cells became hormone-positive. “C” ﬁrst exon-speciﬁc expression was
not detected. The regulation of Nkx2.2 exons that leads to the speciﬁc
Nkx2.2-expression in early pdx1-positive epithelium has not yet been
determined.
Early expression of Nkx2.2 may play a role in pancreatic duct
formation in zebraﬁsh (Pauls et al., 2007), but in Nkx2.2 null mutant
mice the only pancreatic defects are endocrine. Speciﬁcally, these mice
develop with no detectable β-cells, an 80% reduction in α-cells, a
“modest” reduction in PP-cells, and no effect on δ-cells (Sussel et al.,
1998). There were a large number of cells that later were identiﬁed as
ghrelin-positive ɛ-cells,withnoglucagon co-expression, thus suggesting
that Nkx2.2 normally may induce insulin-positive differentiation and
repress ɛ-cell formation (Sussel et al., 1998; Prado et al., 2004).
Consistentwith its role in β-cell formation, Nkx2.2 can bind and activate
mafA (see “MafA and mafB” section) (Raum et al., 2006) and insulin
genes (Cissell et al., 2003). In addition, through creation of an Nkx2.2-
engrailed fusion repressor construct expressed under the pdx1
promoter, the Sussel laboratory showed that the repressor function of
Nkx2.2was normally necessary for enhancingα-cell differentiation, and
for suppressing ɛ-cell formation (Doyle et al., 2007). A double null
mutant mouse for Nkx2.2 and neuroD had rescue of many α- and PP-
cells, and suppression of ɛ-cells, suggesting that neuroD may mimic or
replace the Nkx2.2 repressor function (Chao et al., 2007).
Nkx6.1 and Nkx6.2
Nkx6.1 and Nkx.6.2 are also members of the NK homeodomain
protein family, which are very similar (Vallstedt et al., 2001) and both
appear to play a central role in pancreatic, and speciﬁcally β-cell
development. A role for Nkx6.1 and Nkx6.2 in pancreatic development
was suggested by their expression in all early pancreatic endodermal
cells (Sander et al., 2000; Oster et al., 1998a; Oster et al., 1998b;
Pedersen et al., 2005; Henseleit et al., 2005). Like Nkx2.2, Nkx6.1
appears to be a marker of multipotent pancreatic progenitor cells
(Chen et al., 2007). Pdx1 expression precedes Nkx6.1 and 6.2, and
pdx1 null mutant mice have only a few Nkx6.1-positive cells, but with
no change in the number of Nkx6.2-positive cells. These results
suggest that Nkx6.1 is likely downstream of pdx1, whereas Nkx6.2 is
not (Pedersen et al., 2005). At around E15, Nkx6.1 expression becomes
restricted to insulin-positive cells (Sander et al., 2000), whereas
Nkx6.2 becomes restricted to glucagon-positive and amylase-positive
cells. Nkx6.1 continues to be expressed in mature β-cells, suggesting
an ongoing role in mature β-cell function (Sander et al., 2000). Nkx6.2
is extinguished in the developing pancreas after E15.5.
Single and double null mutant studies for Nkx6.1 and Nkx6.2 have
been performed and suggest that bothmolecules have important roles
and suggest that both molecules have important roles in pancreas
development (Henseleit et al., 2005). Nkx6.1 null mutantmice have an85% reduction in β-cells, whereas Nkx6.1/Nkx6.2 double null mutant
mice have a 92% reduction, suggesting an important role for Nkx 6.1 in
the generation of β-cells, with some compensatory ability of Nkx6.2 to
generate β-cells (Sander et al., 2000; Henseleit et al., 2005). The β-cell
defect was speciﬁcally at the secondary transition, since the insulin-
positive cell population was unable to expand after E13 (Sander et al.,
2000). Interestingly, β-cell loss in Nkx6.1 null mutant mice could be
rescued by transgenic expression of either Nkx6.1 or Nkx6.2 under the
pdx1 promoter, but not under the ngn3 promoter. These results
suggest that Nkx6.2 can replace Nkx6.1 function if expressed in the
proper cell, and also that early Nkx6.1 expression, prior to ngn3
expression, is necessary for β-cell formation (Nelson et al., 2007),
though other later roles for Nkx6.1 in β-cell function seem likely.
Nkx6.1 normally is able to repress Nkx6.2 expression, and in the
absence of Nkx6.1, Nkx6.2 is upregulated speciﬁcally in the early
pdx1-positive progenitor cells, perhaps being involved in the early
commitment of β-cells. Early Nkx6.2 expression appears to be key to
endocrine cell generation since Nkx6.2 is expressed in ngn3-positive
cells just prior to ngn3 expression, and then Nkx6.2 quickly turns off in
those cells, perhaps due to ngn3-induced suppression (Henseleit et al.,
2005). Although Nkx6.2 null mutant mice had normal pancreatic
development, Nkx6.1/Nkx6.2 double null mutant mice had a 65%
reduction in α-cells, suggesting an important role for Nkx6.2 in α-cell
formation, and also suggesting that Nkx6.1 is fully capable of
compensating for the absence of Nkx6.2 in α-cell development.
MafA and mafB
MafA and mafB are members of a large family of basic leucine-
zipper transcription factors that are active in many developmental
processes. MafA has been identiﬁed as speciﬁc to pancreatic β-cells
(Olbrot et al., 2002; Matsuoka et al., 2003); and is a critical regulator of
the insulin gene. Theβ-cell speciﬁcity ofmafA is attributed to a speciﬁc
region (“region 3”) of its promoter that binds pdx1, Nkx2.2, and
HNF3β/FoxA2 (Raum et al., 2006). MafA is ﬁrst expressed in insulin-
positive cells that form during the secondary transition (Matsuoka et
al., 2004; Nishimura et al., 2006). MafA is not necessary for β-cell
formation and mafA null mutant mice have overall normal pancreatic
development. MafA may, however, play a role in β-cell function in a
mature animal (Zhang et al., 2005). It appears that the mafA-positive
insulin-positive cells in the secondary transition of development may
derive from mafB/insulin double-positive progenitor cells (Artner et
al., 2006, 2007; Nishimura et al., 2006). MafB is expressed early in
pancreatic endocrine development in some ngn3-positive cells, and
then in insulin and glucagon-positive cells (Gu et al., 2004; Artner et al.,
2006). As the pancreas develops, mafB is turned off in developing
insulin-positive cells as they transition from immature to mature β-
cells (Nishimura et al., 2006). This transition from mafB to mafA
appears to depend on mafB function, since mafB binds and activates
the mafA gene (Artner et al., 2007). In mafB null mutants, there is
delayed development of early insulin-positive and glucagon-positive
cells, and a 50% reduction in insulin-positive and glucagon-positive
cells overall, with an abundance of hormone-negative cells that appear
otherwise to be of the endocrine lineage. Thus, mafB appears to be a
key regulator of α- and β-cell maturation (Artner et al., 2007).
HNF cascade
Three HNF factors: HNF6/onecut1, vHNF1 (also called TCF2 and
HNF1β), and HNF3β (now FoxA2) together appear to have an
interwoven, complex set of interactions that all impact on pancreatic
development, starting from the earliest pancreatic speciﬁcation, all
the way through to mature pancreatic cell differentiation and
function. HNF6 or onecut1 is a cut homeodomain protein that is
expressed in the endoderm as early as E8 at the foregut-midgut
junction (Lemaigre et al., 1996; Poll et al., 2006; Pierreux et al., 2004)
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endoderm and bound to HNF6 regulatory elements (Poll et al., 2006;
Haumaitre et al., 2005, and Barbacci et al., 1999). Aggregated chimeras
were used to generate vHNF1 null mutant embryos. These embryos
were found to secondarily lack HNF6 expression, and to have ventral
pancreatic agenesis and an atrophic dorsal pancreas (Haumaitre et al.,
2005). A similar pancreatic hypoplasia also occurs in both humans and
zebraﬁsh that have vHNF1/HNF1β mutations (Barbacci et al., 2004;
Sun and Hopkins, 2001). HNF6, in turn, can regulate expression of
HFN3β/FoxA2, which is necessary for gut formation (Weinstein et al.,
1994) and binds and activates the pdx1 gene (Wu et al., 1997). HNF3β/
FoxA2 is not, however, necessary for pancreas formation since
endoderm-speciﬁc deletion of HNF3β/FoxA2 had no effect on
pancreas development (Lee et al., 2005).
After early prepancreatic endodermal expression, HNF6, vHNF/
HNF1β, and HNF3β/FoxA2 are then all expressed in the early
pancreatic epithelium at E9 to E10 (Rausa et al., 1997; Jacquemin et
al., 2003; Maestro et al., 2003). HNF6 appears to be a key determinant
of pancreas speciﬁcation, and it was found that HNF6 null mutant
mice had a severely reduced ﬁeld of pancreas-speciﬁed endoderm
(Jacquemin et al., 2003). These HNF6 null mutant mice are thus born
with a hypoplastic pancreas (Jacquemin et al., 2000, 2003). The
reduced pancreatic ﬁeld in these HNF6 null mutant mice may be due
to inadequate pdx1 expression since HNF6 can bind the pdx1 gene.
HNF6 in the early pancreatic epithelium may also activate vHNF1
to initiate formation of endocrine progenitors in early pancreaticFig. 15. Carboxypeptidase 1 (cpa1) expressing cells can serve as multi-potent progenitor cel
lineage-tagged to express β-galactosidase. Injection of tamoxifen at E10.5, E11.5, and E12.5 in
that cpa1-positive cells will give rise to endocrine cells (yellow cells in A, B, and C), duct cells (
of gestation, the cpa1-positive cells are only able to give rise to acinar cells (yellow cells inepithelium (Maestro et al., 2003). Although the ngn3 gene can be
bound and activated by HNF6, and ngn3-positive cells are reduced in
HNF6 null mutant mice (Jacquemin et al., 2000), the control of
endocrine cell generation by HNF6 appears to be through vHNF1/
HNF1β expression in pancreatic epithelial cells. As a parallel, HNF6 has
been shown to act upstream of vHNF1/HNF1β in bile duct formation
(Clotman et al., 2002). Since ngn3-positive cells are thought to have a
low proliferative potential, and vHNF1/HNF1β-positive pancreatic
epithelial cells appear to be strongly proliferative, it suggests that
HNF6-induced vHNF1/HNF1β-positive epithelial cells are a key highly
expandable endocrine progenitor pool that gives rise to the less
proliferative ngn3-positive cells. The CPA1/PTF1a-double positive cells
that recently were demonstrated to be possible ngn3-negative
endocrine progenitors (see Fig. 15 and “Overview of endocrine
pancreas lineage selection” section) (Zhou et al., 2007) may in fact
be regulated by vHNF1/HNF1β, since PTF1a has a vHNF1/HNF1β-
binding site (Haumaitre et al., 2005). In addition, vHNF1/HNF1β
regulates multiple endocrine-inducing signals (BMP, FGF, retinoic
acid) in zebraﬁsh (Song et al., 2007). Late in gestation, HNF6 turns off,
which is necessary for what seems to be a normal β-cell inhibition of
non-β-cell endocrine growth (Gannon et al., 2000).
The major function of HNF3β/FoxA2 in pancreatic development
appears to be in the maturation of endocrine cells (Lee et al., 2002,
2005). HNF3β/FoxA2 is necessary for pdx1 expression in β-cells
(Gerrish et al., 2000; Sund et al., 2001). Endoderm-speciﬁc HNF3β/
FoxA2 ablation led to development of very fewglucagon-positive cells,ls early in embryonic development. Here, the cpa1-positive cells and their progeny are
duces conditional lineage-tagging at E11–12, E12–13, and E13–14, respectively, showing
red cell in ducts of E, F, and G), as well as acinar cells (yellow cells in E, F, and G). After E14
H) (with permission, Zhou et al., 2007).
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is also necessary for glucagon hormone expression in developing and
mature α cells (Lee et al., 2005).
Sox9
Sox9 may serve as a key mediator of the commitment of ngn3-
positive endocrine progenitors. Sox9 is expressed during pancreatic
development (Piper et al., 2002; Lioubinski et al., 2003; Lee and Saint-
Jeannet, 2003; Seymour et al., 2007) and it seems that Sox9 marks a
population of pancreatic progenitor cells that can give rise to all
pancreatic cell types (Akiyama et al., 2005), and importantly Sox9 is
necessary for maintaining the progenitor state as loss of function Sox9
mutants showed pancreatic hypoplasia due to the depletion of a
progenitor cell pool (Seymour et al., 2007). Sox9 is expressed in
hormone-negative epithelial cells in a similar expression pattern as
vHNF1/HNF1β and HNF6, and there are direct interactions between
Sox9 protein and the regulatory elements of these two HNF genes,
suggesting a role for Sox9 in mediating HNF6 and vHNF1/HNF1β
control over the formation of ngn3-positive cell populations (Lynn et
al., 2007b; Seymour et al., 2007). Consistent with cooperative
functions of Sox9 and HNF6, conditional deletion of Sox9 in pancreatic
epithelial cells led to the formation of cystic duct structures similar to
HNF6 null mutants, with absence of pancreatic endocrine cells
(Seymour et al., 2007). In addition, Sox9 can bind and upregulate
the ngn3 gene, and Sox9 appears to be transiently co-expressed with
ngn3 (Lynn et al., 2007b; Seymour et al., 2007). Given that precursors
to ngn3-positive cells are likely hes1-positive, with ngn3 then turning
on when hes1 turns off (Jensen et al., 2000c; Zhou et al., 2007), Sox9
was found to frequently co-localize with hes1 (Seymour et al., 2007),
perhaps mediating the transition of endocrine progenitors from a
non-endocrine hes1-positive/ngn3-negative state to a hes1-negative/
ngn3-positive endocrine-committed state. Persistent expression of
Sox9, likely through signal integration with notch signaling, appears
to maintain the progenitor population of epithelial cells.
Myt1, GATA factors, HB9, Sox4, Isl1, Hex, Prox1, and Brain4
Myt1 was identiﬁed in an embryonic pancreas screen, and the
gene encodes two different zinc-ﬁnger transcription factors (Myt1a
and 1b) that can potentially interact with ngn3 (Gu et al., 2004).
These two factors are expressed in the developing pancreas in a
pattern similar to ngn3 (Gu et al., 2004; Wang et al., 2007). A
dominant-negative form of Myt1a expressed in the ngn3 domain can
block α- and β-cell development by 30% and 40%, respectively. Myt1
null mutant mice developed abnormal multi-hormone-expressing
pancreatic endocrine cells. Further roles for Myt1 may have been
masked by compensatory expression of paralogs Myt1l and Myt3.
Thus, overall Myt1 appears to be an important regulator of pancreatic
endocrine cell differentiation.
The homeodomain protein Hlxb9, or HB9, is expressed in the
pancreatic domain of the foregut, preceding pdx1 expression (Li and
Edlund, 2001). Subsequently it is present in the early pancreatic
epithelium, and then after E13 is localized to islet cells, and in the
adult islet speciﬁcally only in β-cells (Harrison et al., 1999; Li et al.,
1999). The normal downregulation of HB9 after E12 in the epithelium
appears to be critical for further pancreatic development since
transgenic overexpression of HB9 using a pdx1-HB9 construct led to
global pancreatic hypoplasia and pancreatic intestinalization (Li and
Edlund, 2001). HB9 is important for dorsal pancreatic development
and formation of all β-cells since an HB9 null mutant mice developed
speciﬁcally without a dorsal pancreas, and the remaining pancreas
showed a 65% reduction in β-cells.
Sox4 is expressed in early pancreatic buds, and then focuses to the
islets. Null mutant embryos died by E14.5, but null mutant cultured
pancreatic explants had reduced endocrine cell differentiation and alack of islet formation (Wilson et al., 2005). In zebraﬁsh, Sox4 has two
paralogs, 4a and 4b. Sox4b is localized to endocrine cells, and 4b
morphants speciﬁcally lacked α-cells due to down-regulation of Arx
(Mavropoulos et al., 2005).
Isl1 is a lim homeodomain protein discovered based on its ability to
bind the insulin gene, and is expressed both in early pancreatic
epithelium, as well as in the dorsal mesenchyme in a pattern similar to
pbx-1 (Ahlgren et al.,1997; Kimet al., 2002). Isl1-positive cells are post-
mitotic and likely downstreamof neuroD andupstreamof pax6 (Jensen
et al., 2000a). Isl1 is necessary for survival of the dorsalmesenchyme as
null mutant embryos have no dorsal mesenchyme over the dorsal bud.
These embryos lack a dorsal pancreas, but die at E9.5, making ventral
pancreas development difﬁcult to evaluate. Embryonic pancreas
explant cultures, however, showed that even with replenishment of
the absent dorsalmesenchyme by adding backwild-typemesenchyme,
only exocrine/acinar pancreas developed, still with no pancreatic
endocrine cells. Thus, like pbx-1, isl1 in the epithelium is necessary, cell
autonomously, for development of all endocrine cells, whereas isl1 in
themesenchyme appears to benecessary for productionof an exocrine/
acinar-inductive factor (Ahlgren et al., 1997).
GATA4 and GATA6 are zinc-ﬁnger transcription factors that have
been shown to be expressed in the developing pancreas (Ketola et al.,
2004; Ritz-Laser et al., 2005; Decker et al., 2006). Null mutant mice for
these GATA factors die early in development, precluding pancreatic
analysis. To circumvent this early lethality, two approaches were used.
First, GATA4 or GATA6 were fused to an engrailed repressor domain,
and expressed under the pdx1 promoter to mimic a pancreas-speciﬁc
nullmutation (Decker et al., 2006). GATA4-engrailedmicewere normal,
but expression ofGATA6-engrailed under a pdx1promoter led to severe
pancreas disruption or agenesis, suggesting a key role for GATA6 in
pancreas speciﬁcation. A second approach was to use the tetraploid
embryonic stem cell aggregation technique to generate GATA4 and
GATA6 null mutant mice. In both cases, signiﬁcant disruption or
absence of the ventral pancreas was seen (Watt et al., 2007).
Hex, a hox-related homeodomain protein is expressed in the early
pre-pancreatic foregut, and then in the pancreatic epithelium from
E13 to E16 (Bort et al., 2004). Prior to pancreas formation, hex is
expressed in the anterior leading edge of the ventral foregut
endoderm. There hex induces proliferation of the endoderm leading
to the hex-expressing endoderm growing further away from the
cardiogenic mesenchyme, which in turn allows development of the
ventral pancreas (Jung et al., 1999; Deutsch et al., 2001b).
Prox1 is a homeodomain protein that marks pancreatic and liver
progenitor cells in the endoderm (Burke andOliver, 2002), and continues
to be expressed in the developing pancreas, becoming focused to ngn3-
positive cells and endocrine cells and ducts by E15. Prox1 appears to play
an important role in pancreatic development since null mutant mice die
at E15 with a small pancreas, and with loss of secondary transition
endocrine cells due to premature cell cycle exit (Wang et al., 2005).
Brain4 is a pou-domain protein that was identiﬁed based on its
ability to bind and activate the glucagon gene (Hussain et al., 1997). It
is restricted to α-cell progenitors (Jensen et al., 2000a; Heller et al.,
2004) and persists in mature α-cells and in a few PP-cells in the late-
gestation embryonic pancreas. Brain4 is not necessary for α-cell
formation, as evidenced by the presence of α-cells in the brain4 null
mutant mouse (Heller et al., 2004). Brain4 can, however, drive
glucagon expression in β-cells in a pdx1-brain4 transgenic mouse.
MicroRNA
MicroRNA's have recently been implicated in pancreatic develop-
ment. MicroRNA's are small 20-to-22 base RNA molecules that are
derived from larger primaryRNAtranscripts through intranuclear (Drosh
enzyme) and cytosolic (Dicer enzyme) processing. These small RNA
molecules are able to regulate gene expression at the post-transcrip-
tional level through either silencing or mRNA degradation. MicroRNA's
28 G.K. Gittes / Developmental Biology 326 (2009) 4–35were found to play a role in normal β-cell function (Poy et al., 2004), and
more recently have been studied in developing pancreas. In zebraﬁsh,
inhibition of a speciﬁc microRNA (mi-375) was found to disrupt normal
islet formation, resulting in scattered islet cells (Kloosterman et al.,
2007). Inmouse embryos, pancreatic mIR-375was localized to the ducts
and epithelium (Lynn et al., 2007a). Pancreas-speciﬁc deletion of Dicer,
which results in failure to produce mature microRNA, led to a global
disruption of pancreatic architecture, with ductal ectasia and a particular
loss of β-cells, reminiscent of the HNF6 null mutant phenotype (Lynn et
al., 2007a). These effectswere thought to bemediated through enhanced
notch signaling with elevated hes1 levels.
Along similar lines, a role for microRNA's in post transcriptional
regulation of ngn3, the hes1 target gene, has been identiﬁed in
pancreatic regeneration. Ngn3was surprisingly absent in regenerating
islets after pancreatectomy (Lee et al., 2006). This absence in the
pancreatectomy model was recently explained as possibly due to
microRNA suppression speciﬁcally of the 3′UTR of neurogenin3
transcripts, since a 200-fold increase in the level of neurogenin3
mRNAwas seen in these post-pancreatectomy specimens, but without
detectable ngn3 protein (Joglekar et al., 2007).
Other RNA binding and inhibiting molecules include Vg1RBP,
which was identiﬁed as an RNA binding protein that binds to an
untranslated region of a newly identiﬁed shirin gene. Xenopus
morphants for this binding protein had no insulin or pdx1 expression,
and ectopic expression of this RNA binding protein led to ectopic
pancreas (Spagnoli and Brivanlou, 2006).
Summary and overview of endocrine pancreas lineage selection
The greatest stimulus to pancreatic developmental biological
research comes from a desire to ﬁrst engineer progenitor or stem
cells into mature β-cells for the treatment of diabetes, and second to
better understand the mechanisms of exocrine lineage selection that
may play a role in the pathogenesis of pancreatic ductal adeno-
carcinoma. Towards these two goals, a better understanding of speciﬁc
mechanisms and pathways by which progenitor cells evolve into
speciﬁc pancreatic cell lineages would seem critical.
In the early foregut, HNF family. by the 10 somite (or E8 stage of
mouse development), the regions of the foregut that will become
dorsal and ventral pancreas. At the transcription factor level, this
speciﬁcation comes in the form of pdx1/PTF1a co-expression, which
diverts cells away from duodenal, hepatic, and bile duct fates. In the
absence of pdx1 or PTF1a, an evagination with a few endocrine cells
still forms, though it is likely that these cells are only vestigial in nature.
After this early evagination of dorsal and ventral pancreas, with the
need for pancreatic determination no longer an issue, multiple factors
then seem to determine the selection between acinar, endocrine, and
ductal lineages. The overlying mesenchyme, with FGF's, canonical
Wnts, and notch signaling, together with the presence of laminin and
certain proteoglycans, all play a key role in favoring acinar and ductal
differentiation instead of endocrine differentiation. Notch signaling is
a critical mediator of this ductal/acinar-versus-endocrine decision.
Absence of notch-induced hes1 activity allows ngn3 expression and
subsequent commitment to the endocrine lineage.
Notch signaling seems to actively drive duct formation in certain
progenitor cells, and such ductal progenitor cells speciﬁcally express
pdx1 only within the E19 to E12 gestational window (Gu et al., 2002).
Beyond the initial notch suppression of endocrine lineages, later
persistence of notch signaling will actually prevent acinar differen-
tiation, due to the notch-induced RBP-Jκ binding of PTF1a. As
progenitor epithelial cells commit to the acinar lineage, notch-
regulated RBP-Jκ is displaced by notch-independent RBP-Jl to start
to form the mature PTF1 transcriptional complex, which allows acinar
maturation to occur. The decision between acinar and endocrine
commitment during the E11 to E14 gestational period appears to occur
at the growing tips of the epithelial branches (Zhou et al., 2007) (seeFig. 15). There, PTF1a/CPA1-positive cells will make the commitment
(likely under control of notch signaling) to either leave the growing tip
and become ngn3-positive, or instead to stay at the tips as a progenitor
cell. Then, after E14, those remaining PTF1a/CPA1-positive tip cells are
committed to the acinar lineage. The control of the ﬂow of ngn3-
negative epithelial cells to become ngn3-positive, endocrine-com-
mitted cells seems to involve important interactions between HNF6,
vHNF1/HNF1β, and sox9, possibly in that order hierarchically, to
determine ngn3-positive-commitment.
Within the endocrine cell compartment, ngn3-positive cells reside
at the top of the hierarchy, and all pancreatic endocrine cells go through
an ngn-3 positive stage. Beyond ngn-3-positive-commitment, several
studies have investigated the mechanism by which the ﬁve separate
endocrine lineages (α-, β-, γ-, PP-, and ɛ-cells) are determined among
the ngn3-positive cells. Early in pancreatic differentiation, cells are
known to be double-positive for insulin and glucagon, and possibly
other peptides (reviewed in Teitelman (2004)). It appears, however,
through lineage-tagging studies, that these insulin-glucagon double
positive cells do not give rise to mature α- or β-cells (Herrera, 2000),
and likely undergo apoptosis. Early studies have shown the presence of
endocrine cells that express PYY (Upchurch et al., 1994). These PYY-
expressing cells were originally identiﬁed as possibly PP-expressing
cells (Herrera et al., 1991) or NPY-expressing cells (Teitelman et al.,
1993), based on what may have been cross-reacting antibodies. PYY
may be a marker of early endocrine committed cells, since it is co-
expressed with all endocrine cells in the early pancreas, and then is
suppressed in many maturing cells, especially maturing β-cells, but is
still expressed at low levels in many mature endocrine cells (Liu et al.,
2006; Myrsen-Axcrona et al., 1997). Various experimental lineage-
tracing approaches suggest that the precursors of α- and β-cells go
through a PP-positive phase (Herrera et al., 2002).
At the transcription factor level, there is an early decision between
the β/δ-cell-lineage versus the α/PP-cell-lineage. This early decision is
mediated by Arx and pax4, which are both expressed in ngn3-positive
cells. Arx and pax4 inhibit the effects of one another, but perhaps
unknown additional factors are needed to determine the overall
balance between these two factors. Arx dominance in a cell favors the
α/PP-cell lineage, whereas initial pax4 dominance within a cell favors
β/δ cells (see Fig. 14). Interestingly, once the β/δ-cell decision is made,
pax4 becomes a δ-cell suppressor speciﬁcally in β/δ-committed cells,
since Arx/pax4 double-knockout animals have an overabundance of δ-
cells. The identiﬁcation of a transcription factor (or factors) required for
the speciﬁcation of δ-cells, PP-cells or ɛ-cells remains to be determined.
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